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ABBREVIATIONS 
 
2AG, 2-arachidonoylglycerol  
7NI, 7-nitroindazole  
AB, angular bundle 
AC, associational commissural pathway 
ACEA, 2’-chloroethylamide 
AD, after discharge 
AEA, anandamide 
ANOVA, analysis of variance 
ARG, arginine 
BG, basal ganglia  
CA1, cornus ammonis 1 
CA3, cornus ammonis 3 
cAMP/PKA, cyclic adenosine 
monophosphate/protein kinase A 
CAP, capsaicin 
CB, cannabinoids 
CB1R, cannabinoid receptor type 1 
CB2R, cannabinoid receptor type 2 
CCK, cholecystokinin 
cGMP, cyclic guanosine monophosphate 
CNG, cyclic nucleotide-gated 
CNS, central nervous system 
CPZ, capsazepine 
CTR, control 
D%, % difference 
DG, dentate gyrus 
DSE, depolarization-induced suppression of 
excitation  
DSI, depolarization-induced suppression of 
inhibition 
eCB, endocannabinoids 
GLU, glutamate 
GP, globus pallidus 
KA, kainic acid 
LEC, lateral entorhinal cortex 
LTD, long-term depression 
LTP, long-term potentiation 
mAChr, muscarinic acetylcholine receptor 
MDA, maximal dentate gyrus activation 
MEC, medial entorhinal cortex 
MF, mossy fibers 
NO, nitric oxide 
NOS, NO synthase 
eNOS, endothelial NOS 
iNOS, inducible NOS 
nNOS, neuronal NOS 
NT, neurotransmitter 
ODQ, 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-
1-one 
PKG, cGMP-dependent protein kinase 
PLC, phospholipase C 
PLD, phospholipase D 
PP, perforant path 
Sb, subiculum 
SC, Schaffer collateral 
SE, status epilepticus 
sGC, soluble guanylyl cyclase 
STN, subthalamic nucleus 
THC, tetrahydrocannabinol 
TLE, temporal lobe epilepsy 
TRPV1, transient receptor potential vanilloid 
type 1 
WIN, (R)-(+)WIN 55,212-2.  
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INTRODUCTION 
Temporal Lobe Epilepsy: focus on bioelectric substrates of hyperexcitability 
Epilepsy is broadly recognized as a multi-factorial neurologic disorder, defined by a state of 
recurrent, spontaneous seizures (Stafstrom and Carmant, 2015). In patients, epileptic seizures 
are basically classified into generalized and focal (Scheffer et al., 2016). Generalized seizures 
engage the entire cortex, hence patients suffer from a complete loss of consciousness. Focal 
seizures originate from a localized brain region, thus retaining consciousness, unless they 
spread to neighbouring regions via local cortical connections, or to trans-hemispheric areas 
via long-association pathways such as the corpus callosum, in that case they secondarily 
generalize. 
It is common thought that animal models of epilepsy are essential for better understanding the 
basic mechanisms of processes leading to epilepsy and therefore improving pharmacotherapy 
(Lӧscher, 2011). In acute models, epileptic seizures are provoked by electrical or chemical 
stimulation in naïve, non-epileptic animals, while the term ‘chronic’ refers to models that use 
animals that have been chronically made epileptic as above-described or animals with 
genetically-induced epilepsy (Fig. 1). Animal models of temporal lobe epilepsy (TLE) serve 
to expand knowledge on the most frequent type of focal seizure in adulthood (Wieser, 2004; 
Hauser et al., 1996) and share with human epilepsy many fundamental features. Remarkably, 
they are characterized by: a) localization of seizure foci within the limbic system, especially 
in the hippocampus and entorhinal cortex (Bartolomei et al., 2005); b)  high incidence of 
hippocampal sclerosis (Mathern et al., 1997) and c) several molecular changes, including 
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alterations of genes and receptors (Bednarczyk et al., 2016; Karlócai et al., 2011; Ben-Ari and 
Dudek, 2010). 
 
Fig. 1. Different epileptogenic mechanisms of seizures in animal models (Lӧscher, 2011). 
Particularly, brain structures typically involved in experimental temporal lobe epilepsy and 
subjected to neuronal alteration are cornus ammonis 1 and 3 (CA1 and CA3) and the dentate 
hilus of the hippocampus, but the damage can also extend to extra-hippocampal regions, such 
as the entorhinal cortex or the amygdala (Ben-Ari and Dudek, 2010; Ben-Ari et al., 2008; 
1980; see in fig. 2 a schematic representation of the hippocampal network). Similarly to 
mesial temporal sclerosis in human temporal lobe epilepsy, brain damage can either be quite 
limited (i.e. only a few hundred neurons loss) or wider, but patterns are variable across 
structures and animal models (Ben-Ari and Dudek, 2010).  
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Fig. 2. Hippocampal network. The hippocampus receives inputs from the entorhinal cortex, that 
forms connections with the dentate gyrus (DG) and CA3 pyramidal neurons via the Perforant Path 
(PP). The axons of the PP arise principally in layers II and III of the entorhinal cortex and can be 
segregated into lateral and medial pathways (LPP and MPP, respectively), depending on whether the 
fibers arise from the lateral or medial entorhinal cortex (LEC and MEC, respectively). CA3 neurons 
receive input from the DG via the mossy fibers (MF). CA3 neurons provide axons to ipsilateral CA1 
pyramidal neurons via the Schaffer Collateral Pathway (SC) and to contralateral CA1 neurons via the 
Associational Commissural Pathway (AC). Moreover, CA1 neurons receive input directly from the PP 
and send axons to the subiculum (Sb) and in turn send output back to the entorhinal cortex. (as in 
Sharma et al., 2007). 
From a bioelectric point of view, dynamic changes occurring during epileptic seizures are 
rooted on altered excitability phenomena driving seizure initiation and propagation (Morelli et 
al. 2014; Bromfield et al., 2006). The initiation of seizures is defined by the concurrent 
presence of high-frequency bursts of action potentials and hyper-synchronized neuronal 
population. At single-neuron level, the burst of action potentials results from the “paroxysmal 
depolarizing shift” which consists of sustained, plateau-like neuronal depolarization that 
rapidly repolarizes and is followed by hyperpolarization. This prolonged depolarization of 
neuronal membranes is due to influx of extracellular Ca
++
, leading to the voltage-channel 
mediated Na
+
 influx, that generates repetitive action potentials, whereas the subsequent 
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hyperpolarization is mediated by GABA receptor-dependent Cl
−
 influx, or by K
+
 efflux. 
Bursting activity does not normally propagate during functional hyperpolarization that is 
supported by surrounding inhibition. Nonetheless, paroxysmal activation can a) increase 
extracellular K
+
, attenuating hyperpolarizing outward K
+
 currents, b) accumulate pre-synaptic 
Ca
++
, enhancing neurotransmitter release, and c) activate NMDA subtype of glutamate 
excitatory receptor which sustains Ca
++
 influx and repetitive neuronal discharge. In this case, 
spontaneous rapid seizure termination fails and leads to the condition of status epilepticus 
(SE; Bromfield et al., 2006). 
Network mechanisms are of noticeable importance for the regulation of hippocampal 
excitability,  reflecting population activity of pyramidal cells and interneurons (Colgin, 2016; 
Gelinas et al., 2016). Epileptogenic regions are thought to reverberate the pathologically 
altered synchronization of neuronal assemblies (Foffani et al., 2007; Bragin et al., 2002; 
2000). Indeed, epileptic seizures induce a local reorganization of inhibitory and excitatory 
circuits that modify population activity and brain oscillations (Foffani et al., 2007; Siddiqui 
and Joseph, 2005; Nadler et al., 1980), similarly to synaptic reorganization in humans with 
temporal lobe epilepsy (Wieser, 2004). The prevalent idea is that the mossy fibers of the 
dentate granule cells sprout and form novel excitatory synapses on neurons that they do not 
normally innervate (Ben-Ari and Dudek, 2010; Dudek and Sutula, 2007; Represa et al., 
1987). This increased recurrent excitation in combination with the loss of vulnerable 
interneurons, in the dentate gyrus (DG) and CA1 as well, is a fil rouge along many temporal 
lobe epilepsy models, for example kindling and repetitive electric stimulation of the perforant 
path (Bengzon et al., 1997; Sloviter, 1983). Synaptic activity is therefore influenced by 
network phenomena that are driven and enhanced by aberrant glutamatergic firing and also by 
pre- and post-synaptic alterations in the GABAergic control (Siddiqui and Joseph, 2005; 
Nadler et al., 1980). In detail, the main glutamate (GLU) receptors involved in 
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epileptogenesis are: NMDA, especially NR1 subunit, upregulated in epileptic tissue in the 
hippocampus (O’Dell et al., 2012; Sandoval et al., 2011; de Moura et al., 2010) and kainic 
acid (KA) receptors, particularly GLU-K1 and GLU-K2 subunits (Ben-Ari et al., 2008; 
Epsztein et al., 2005). Though, only KA receptors operate the new aberrant synapses, whereas 
naïve ones rely on AMPA receptors (Ben-Ari et al., 2008; Epsztein et al., 2005). Loss of 
inhibitory control involves: qualitative and quantitative changes in GABAA receptor subunits 
(Fritschy et al., 1999); modulation by other neurotransmitters (Chamberlain et al., 2012; 
Oliveira et al., 2010) and phenotypic changes of receptor subtypes from hyperpolarizing to 
depolarizing activity (Galanopoulou, 2007).  
In the light of this evidence, exploring the possible synaptic targets underlying 
pathophysiological alterations of neural transmission could promote advancement in the 
knowledge of hyperexcitability phenomena. Indeed, the modulation of neuronal transmission 
in the central nervous system (CNS) deserves great interest in orienting the development of 
new anticonvulsants towards targets that can influence bioelectric balance in neuronal 
processes. In this view, several elements have attracted attention so far. Among these, 
endocannabinoid system stands out for its variegated modulatory activity, exerted on classic 
receptor-mediated mechanism or on further molecular players such as nitric oxide.    
Cannabinoid control of neuronal activity and epileptic seizures 
Endocannabinoid (eCB) system contributes to synaptic function by various mechanisms and 
is involved in physiological processes such as memory formation, food intake, pain sensation 
and rewarded behaviour. Within the brain, CB1R (cannabinoid receptor type 1) can be found 
in cortical and subcortical regions that are involved in superior functions, such as the basal 
ganglia, substantia nigra, hippocampus, cerebellum and brain stem. Classically, 
endocannabinoids modulate neurotransmitter signalling via a retrograde, feedback 
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mechanism. They are synthesized on-demand in the post-synaptic terminal, after elevation of 
Ca
2+
 levels, by Ca-dependent synthesizing enzymes. Then, eCBs are released in the synaptic 
cleft and target pre-synaptic CB1R coupled to the  Gi/o proteins (Howlett et al., 2002; Wilson 
and Nicoll, 2001). At the cortical level, CB1R control neuronal activity by affecting both 
excitatory and inhibitory neurotransmission. In the hippocampus, the on-demand production 
of endocannabinoids from over-activated post-synaptic cells inhibits neurotransmitter release 
(Marsicano et al., 2003) specifically from two neuronal populations of CA1 area: 
cholecystokinin (CCK)-positive GABAergic interneurons and excitatory glutamatergic 
terminals onto pyramidal cells (Katona et al., 2006; Kawamura et al., 2006, Wilson and 
Nicoll, 2001). In accordance with this, CB1R receptors can modulate stimulus-evoked 
inhibitory or excitatory post-synaptic potentials (Castillo et al., 2012; Ohno-Shosaku et al., 
2001;Wilson and Nicoll, 2001; Wilson et al., 2001). In detail, pre-synaptic CB1R can regulate 
short-term plasticity mechanisms, in which CB1Rs are activated for a few seconds; then, the 
βγ subunits of G-proteins inhibit pre-synaptic Ca2+ influx in the cytosol through voltage-gated 
Ca
2+
 channels (Brown et al., 2003; Kreitzer and Regehr, 2001; Wilson et al., 2001; fig. 3). 
Whereas, eCB-mediated long-term plasticity requires inhibition of adenylyl cyclase and 
downregulation of the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) 
pathway (Castillo et al., 2012; Chevaleyre et al., 2006; fig. 3). In the context of retrograde 
eCB function, CB2R (cannabinoid receptors type 2) distribution and function have been 
widely recognized in the immune system so far. Though, growing evidence support that CB2R 
participates in a variety of brain processes (Den Boon et al., 2012; Morgan et al., 2009; Cabral 
et al., 2008; Fernández-Ruiz et al., 2007; Van Sickle et al., 2005). In particular, it is reported 
that CB2R mediate an activity-induced self-inhibition in medial prefrontal cortex, decreasing 
neuronal firing (den Boon et al., 2012). 
 
 9 
 
 
Fig. 3. Classical retrograde signalling mechanism of endocannabinoid system. Main downstream 
targets of CB receptors activation and subsequent Gi-protein stimulation are: (1a) inhibition of 
adenylyl cyclase (AC) activity, (1b) membrane hyperpolarization after modulation of K
+ 
and Ca
2+
 
channels, (1c) activation of protein kinase cascades such as MAPK pathway. These actions result in 
the inhibition of neurotransmitters (NT) release. (2) Usually, when glutamate is released from pre-
synaptic terminals stimulates both ionotropic and metabotropic glutamate receptors, leading to post-
synaptic depolarization through Ca
2+
 entrance and Gq-protein activation. (3) High Ca
2+
 concentration 
stimulates the synthesis of endocannabinoid (2-arachidonoylglycerol, 2AG, and anandamide, AEA) 
through phospholipase C and D (PLC and PLD). 2-AG synthesis is also mediated by Gq-protein 
activation. (3) Endocannabinoids are released to the synaptic cleft and activate CB1 and CB2 pre-
synaptic receptors. (figure modified from Flores et al., 2013). 
In addition, eCBs signal is thought to act in a non-retrograde manner recruiting the transient 
receptor potential vanilloid type 1 (TRPV1) and also CB1Rs located on the post-synaptic side 
(Castillo et al., 2012).  TRPV1 are non-selective cation channels, that integrate peripheral 
noxious stimuli activated by natural vanilloids (capsaicin and resiniferatoxin), heat and acids. 
TRPV1 channels, when gated, induce a complex cascade of events, including the release of 
pro-inflammatory mediators and neurotoxicity (Caterina et al., 1997). In particular, TRPV1 
 10 
 
activation augments the membrane permeability to Na
+
 and Ca
++
, thereby modulating 
neuronal excitability (Saffarzadeh et al., 2015; Menigoz and Boudes, 2011; Szallasi and 
Blumberg, 2007;  Cristino et al., 2006). TRPV1 are also reported to influence pivotal 
processes of the hippocampus by modulating mechanisms of synaptic efficiency such as long-
term potentiation (LTP) and long-term depression (LTD) (Fu et al., 2009; Gibson et al., 2008; 
Leite et al., 2005).  
Moreover, by presenting an additional intracellular binding site for anandamide (AEA, the 
major endocannabinoid agonist), TRPV1 has been considered as a possible “ionotropic 
receptor counterpart” for CB1R and CB2R, since many of pharmacological effects of AEA can 
be abolished by TRPV1 antagonism, knockout and desensitization (Ligresti et al., 2016). 
AEA and capsaicin share chemical and pharmacodynamic similarities as full agonists of 
TRPV1 (Szallasi and Blumberg, 2007), whereas other cannabinoids, such as (R)-(+)WIN 
55,212-2 (hereafter, WIN) and 2-arachidonoylglycerol (2-AG), cannot be considered as 
TRPV1 classical agonists and their interference with this receptor is still to be elucidated (Di 
Marzo and De Petrocellis, 2012).  
Considering eCB activity in regulating physiological neuroexcitability, it does not surprise 
that cannabinoids (CB) have caught attention as potential endogenous antiepileptics in the 
brain over the last decades (Hofmann and Franzier, 2013; Monory et al., 2006). Endogenous 
and exogenous cannabinoid agonists have demonstrated CBR-mediated anti-seizure effects 
after systemic administration in both epileptic animals and in vitro models (Blair et al., 2006; 
Wallace et al., 2003; 2001); whereas CB1R antagonists prompt epileptic activity (Deshpande 
et al., 2007, Hofman and Franzier, 2013). In humans, rimonabant (CB1R antagonist) triggered 
paroxysmal events in epileptic patients (Braakman et al., 2009) and a down-regulation of 
CB1R was encountered in human epileptic tissue (Ludányi et al.,  2008). In agreement, our 
laboratory previously yielded evidence that WIN, a CB non-selective agonist, exerts 
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antiepileptic effects in an in vivo model of hippocampal epilepsy; moreover, WIN was 
significantly, but incompletely, antagonized by CB1R antagonist AM251 (Rizzo et al., 2009). 
The finding of AM251 ineffectiveness when administered alone and its partial antagonism on 
WIN-dependent activity conveyed the idea of the functional involvement of further 
mechanisms underpinning CB antiepileptic effects. In this regard, the action of eCBs, such as 
AEA, on TRPV1 was also found to influence epileptic events and to be challenged by CB1R 
antagonist as well as by capsazepine, the TRPV1 antagonist (Di Marzo and De Petrocellis, 
2012; Manna and Umathe, 2012; Bhaskaran and Smith, 2010; Chavez et al., 2010).  
A predominant line of research supports that these protective effects by CB1R agonists are 
specifically exerted onto excessive glutamatergic release from pyramidal cells (Monory  et al., 
2006; Marsicano et al., 2003). In this regard, cannabinoids are considered to impair normal 
synchronized network activity in the hippocampus, an action that was selectively ascribed to 
the suppression of pre-synaptic glutamate release from excitatory terminals (Maier et al., 
2012). Therefore, cannabinoid influence on hippocampal network oscillations could play an 
important part in aberrant neuronal organization in hyperexcitability. At molecular level, 
CB1R protection against excitotoxicity requires both hyperpolarization of neuronal 
membranes, mainly by increasing K
+
 and decreasing Ca
++
 conductance that provide rapid 
protection, and the induction of intracellular cascades, for long-term adaptive changes. 
Nonetheless, psychoactive effects of cannabinoids have limited so far a comprehensive 
clinical assessment of treatment with phytocannabinoid agonists such as tetrahydrocannabinol 
(THC) and cannabidiol, though individual cases and limited studies tend to support their 
antiepileptic effects for development of symptomatic and prophylactic therapy (Soltesz et al., 
2015, Cilio et al., 2014; Maa and Figi, 2014; Armstrong et al., 2009). Promising trials have 
been successfully carried out to evaluate cannabidiol therapeutic potential in untreatable 
paediatric epilepsies (Ligresti et al., 2016). Noteworthy, cannabidiol is thought to act on Ca
2+
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homeostasis via different ways, one of which could be activation/desensitization of TRPV1 
channels (Iannotti et al., 2014; Jones et al., 2012). 
Besides the intracellular mechanisms above described, the eCB system has several, still 
unexplored points of interaction with other signalling systems, above all nitrergic 
transmission,  that could be implicated in eCB protection from hyperexcitability phenomena. 
Role of nitric oxide on neuronal excitability  
Nitric oxide (NO) is a gaseous molecule synthesized from the oxidation of L-arginine by three 
different isoforms of NO synthase (NOS): the neuronal (nNOS) and endothelial (eNOS) 
constitutive isoforms are calcium activated; the inducible isoform (iNOS) is calcium-
independent. NO targets the soluble guanylyl cyclase (sGC), a cyclic guanosine 
monophosphate (cGMP)-producing enzyme (Feil and Kleppisch, 2008), that acts downstream 
on cGMP-dependent protein kinases (PKG) or cyclic nucleotide-gated (CNG) ion channels, 
regulating intracellular Ca
2+
. In the CNS, nitric oxide participates to neuronal function by 
regulating synaptic plasticity, axonal elongation and normal and pathological excitability 
(Ahern et al., 2002; Kiss and Vizi 2001; Prast and Philippu, 2001; Brenman and Bredt, 1997). 
Indeed, previous researches discovered the nitrergic modulation of neuronal activity in the rat 
basal ganglia (BG) area, comprising striatum, globus pallidus (GP) and subthalamic nucleus 
(STN) (Sardo et al.,  2011; 2009; 2008; 2006). At molecular level, NO can impact on voltage-
gated and ligand-gated channels either switching on the classical cGMP pathway or through 
protein modification (Garthwaite, 2008; Kiss, 2000). Furthermore, NO acts via Ca
2+
-
dependent and -independent processes affecting the release of neurotransmitters i.e. 
glutamate, GABA, acetylcholine, dopamine and noradrenaline (Ohkuma and Katsura, 2001; 
Arancio et al., 1995). Above all, NO interacts with the redox site of the glutamatergic NMDA 
receptor decreasing its response to agonists, especially during ‘‘over-activity’’ (Grima et al., 
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2001; Quesada et al., 1996), and participates to metabotropic GLU receptors-dependent LTP 
(Anwyl, 2009). In the light of this, NO has been potentially considered to heavily influence 
the genesis and the spreading of the epileptiform hyperexcitability (Przegalinski et al., 1996), 
with several experimental observations that have revealed a general increase of NOS 
expression in various models of experimental epilepsy (Lumme et al., 2000; Hara et al., 
1997). Though, no definitive conclusions have been released about a pro- or anti-convulsant 
role so far (Ferraro and Sardo, 2004; Borowicz et al., 2000; de Vasconcelos et al., 2000; Del-
Bel et al., 1997).  
Within the context of hyperexcitability, NO has caught attention since it likely represents a 
target of cannabinoid action and serves as a mediator for numerous CB effects (Bahremand et 
al., 2009; Jones et al., 2008; Kim et al., 2006 b), directly targeted by CB1-activated pathway 
or by post-synaptic TRPV1 (Batista et al., 2015; Aguiar et al., 2014; Bredt and Snyder, 1989). 
In particular, the eCB system and cGMP signalling are reported to be functionally related in 
certain neuronal paradigms (Ghasemi et al., 2007; Howlett et al., 2004; Azad et al., 2001; 
Stefano et al., 1998). For instance, guanine nucleotides can inhibit CB agonists binding 
(Devane et al., 1988), whereas cannabinoid agonists can stimulate both the production of 
cGMP and the translocation of the NO-activated sGC (Jones et al., 2008). In rat microglial 
cells, a CB1-mediated reduction of NO release, involving Ca-independent iNOS isoform, was 
demonstrated (Waksman et al., 1999). Particularly, in the hippocampus the distribution of 
these targets has been described in the pre-synaptic glutamatergic afferents (Burette et al., 
2002). Anatomical evidence point to a co-localization of nNOS and NO-activated sGC in 
synapses supplied with CB1 receptors (Burette et al., 2002; Azad et al., 2001), especially in 
the hippocampus (Makara et al., 2007). Furthermore, cannabinoids were reported to inhibit 
nNOS activity in brain processes, for instance blocking K
+
-induced depolarization (Hillard et 
al., 1999) and reducing voltage-gated Ca
2+
 influx, therefore uncoupling membrane 
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depolarization from nNOS activation (Twitchell et al., 1997). Interestingly enough, it was 
found that neuronal nitric oxide could be engaged in the anticonvulsant properties of CB1 
receptor agonist arachidonyl-2’-chloroethylamide (ACEA), influencing seizure threshold in a 
behavioural model of epilepsy (Bahremand et al., 2009). Nonetheless, the linkage between 
cannabinoid and nitrergic systems in the modulation of hyperexcitability phenomena would 
deserve deeper investigations. 
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AIM 
This research project aimed to deepen knowledge on the role of cannabinoid signalling in the 
context of epileptic hyperexcitability. The pharmacological manipulation of cannabinoid 
receptor pathway is a suitable approach for exploring the contribution of CB1R and CB2R in 
hyperexcitability phenomena, by applying specific exogenous CBR agonists and antagonists. 
Furthermore, the possible implication of nitric oxide in cannabinoid-activated pathways was 
investigated, taking into account its reported function as a neuronal mediator. This was put 
into practice by evaluating cannabinoid effects in presence of several NO-active drugs that 
could reduce or increase NO activity, modifying its production and blocking its downstream 
target, the sGC. Lastly, TRPV1 role on CB antiepileptic effects was assessed by a 
pharmacological characterization of capsaicin and capsazepine alone and in combination with 
a CB agonist, within the framework of paroxysmal phenomena induced in hippocampal 
models of epilepsy. The ultimate goal was to propose putative points of interaction between 
the systems involved in the neuromodulation of hyperexcitability, focusing on the linkage 
among CB receptors, TRPV1 and nitric oxide. 
Two models of acute epileptiform activity were used, the maximal dentate activation (MDA) 
and the acute pilocarpine-induced paradigm, respectively characterized by electrically and 
chemically-evoked seizures (Löscher, 2011; Raza et al., 2001; Mello et al., 1993). In the 
MDA, free of chemical interferences, an excitatory re-entrant loop in the limbic system is 
activated by electric stimulation of the angular bundle (AB) (Stringer and Lothman, 1992). 
This model is defined by the presence of electrically-induced hippocampal bursts of large 
amplitude population spikes, associated with a secondary rise in the extracellular K
+
 and a 
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negative shift of the DC potential (Stringer and Lothman, 1992). The synchronous burst 
discharge of dentate cells, after hyper-activation of a hippocampal–parahippocampal circuitry, 
constitutes a bio-electric marker of acute TLE in the hippocampus that is extensively studied 
as a crucial focus of hyperexcitability processes (Kandel et al., 2014; Stringer and Lothman, 
1989). In the behavioural model of TLE, pilocarpine elicits cholinergic-induced 
epileptogenesis by activating muscarinic receptors in the hippocampus and causes 
spontaneous seizures with typical behavioural symptoms (Curia et al., 2008). The pilocarpine 
model has been widely employed since it reproduces the characteristics of acquired, 
refractory human epilepsy, such as anatomical damage, network reorganization and 
pharmacoresistance to conventional antiepileptic drugs (Curia et al., 2008; Hamilton et al., 
1997; Mello et al., 1993).  
Noteworthy, studies about the pathophysiology of epileptic phenomena may produce 
conflicting results, for instance due to different experimental protocols, animal species and 
pharmacological properties of drugs chosen (Löscher, 2011; Löscher et al., 1991). For this 
reason, when feasible, it was designed an integrated experimental approach, coupling 
electrophysiological and behavioural methods to evaluate the effects of perturbing 
cannabinoid neuromodulatory activity on the genesis and maintenance of epileptic activity in 
the hippocampus, in both anesthetized and freely-moving animals. Comparing 
pharmacological outcomes from these acute TLE models that have distinct epileptogenic 
triggers, allowed to place robust relationship between CB/TRPV1 system and nitric oxide 
signalling within the remit of hippocampal hyperexcitability. This research, investigating on 
several factors underpinning the neurobiological mechanisms of cannabinoid control of 
seizures, may promote the development of novel, non-conventional therapeutic perspectives.  
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MATERIALS AND METHODS 
Animal experiments were conducted in strict accordance with the European Directive on 
animal experimentation (2010/63/EU) and the institutional guidelines, authorized by the 
Italian Ministry of Health. All efforts were made to minimize animal suffering and to reduce 
the number of animals used. 
EXPERIMENTAL MODELS OF TLE 
MDA model 
Surgical procedures 
Male Wistar rats (weight 260–300 g, 2–3 months-old) were anesthetized with urethane (1.2 
g/kg intraperitoneally, i.p.). The trachea was cannulated and the skull exposed. The animals 
were positioned in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, USA) and 
the body temperature was maintained at 37–38°C using a heating pad. Heart rate and pupil 
diameter were monitored during all the experimental session. A craniotomy was performed to 
expose a wide area of the right cerebral cortex, then the dura was removed. A stimulating 
depth electrode (coaxial bipolar stainless steel electrode: external diameter 0.5 mm; exposed 
tip 25–50 µm) was placed in the AB on the right side according to the stereotaxic coordinates 
of the Atlas of Paxinos and Watson (1986) (AB: 1 mm anterior to the interaural line; 3–5 mm 
dorsal to it and 4.4 mm lateral to the midline). A glass recording microelectrode (1–2 µm tip 
diameter, 1.8–2.2 MΩ electrode resistance), filled with 1% Fast Green in 2 M NaCl, was 
stereotaxically placed in the DG on the right side (DG: 6 mm anterior to the interaural line; 
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3.0 mm ventral to the cortical surface and 1.8 mm lateral to the midline). The animal was 
grounded through a subcutaneous Ag/AgCl wire in the scapular region.  
Electrophysiological procedures 
The protocol of MDA originally designed by Stringer and Lothman (1992) was previously 
modified by introducing: a fixed duration of the electrical stimulation, a related way to 
determine the threshold and the stimulation intensity, and a fixed spacing between 
stimulations (Ferraro and Sardo, 2009; Sardo et al., 2009; 2008; 2006). 
Fixed duration (10 s) trains of 20-Hz stimuli were given through the AB stimulating 
electrode. Individual stimuli consisted of 0.3ms biphasic pulses; the stimulus intensity was 
initially below that necessary to elicit any response and it was increased by 100µA steps in 
the following stimulations until MDA occurred (threshold intensity). The stimulus train was 
administered every 2 minutes until a MDA appeared and then every 10 minutes for up to 3 h. 
MDA was recorded by the electrode placed in the DG and it was defined by a shift of the 
extracellular potential in DC-coupled recordings as well as by the presence of bursts of 
population spikes (Fig. 4). Once the MDA was elicited, the percentage of responses to AB 
stimulation was analysed to appraise the effect of pharmacological treatment; the eventual 
absence of MDA response per group  (Fig. 7 c) was taken into consideration to evaluate the 
percentage of protection (% protection) against electrically induced epileptiform events on the 
basis of the following formula: 100 * (total number of no responses to stimulation per 
group/total number of stimulations per group). Furthermore, three parameters describing the 
electrophysiological features of MDA were monitored along each experimental session: time 
of onset (latency) as an indicator of the susceptibility of the DG to respond to stimulation; 
MDA and after discharge (AD) duration to quantify the extent of epileptic discharge (see fig. 
4). In detail, onset is time from the beginning of AB stimulation to the midpoint of the DC 
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potential shift; MDA duration is from the midpoint of the DC potential shift to the point at 
which the evoked paroxysmal EEG events abruptly ceased and AD is from the end of AB 
stimulation to the end of the epileptiform activity.  
The DG bioelectric activity was recorded through a low-level DC pre-amplifier (Grass 7B, 
West Warwick, RI, USA) and then processed by the SciWorks 5.0 package provided by 
DataWave Technologies (Longmont, CO, U.S.A.). 
 
 
 
Fig. 4. Representative MDA trace. Measurements of time of onset (latency), duration of maximal 
dentate gyrus activation (MDA) and after discharge (AD) during and after a stimulus train (400 µA, 
20 Hz) delivered for 10 s to the angular bundle (AB).  
Histological verification 
Recording and stimulating electrode positions were respectively marked through 
iontophoretic Fast Green ejection (50 µA for 10 min) and a small electrolytic lesion (20 mA 
for 10 s.), then they were histologically verified. On completion of each experiment, the 
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animals were anesthetized by an overdose of pentobarbital i.p. and whole-body perfused with 
normal saline, followed by 10% buffered formalin. The brains were removed, post-fixed in 
the same fixative overnight and then cryoprotected in 30% sucrose/PBS. Finally, brains were 
sliced in 30–50-µm serial coronal sections and stained by using Nissl-Cresyl Violet method 
(Sardo et al., 2008; fig. 5). 
Statistical analysis 
A Chi-square (χ2) test was used to compare the % of responses to AB electrical stimulation 
following each drug treatment within the same experimental group and between treatments. 
For co-treated groups, the % of MDA responses was taken into consideration from the last 
drug administration.  
For the studied parameters (the time of onset, MDA or AD durations), data from each animal 
were expressed as % difference (D%) versus the baseline value measured in the last MDA 
response preceding vehicle or drug injection (Fig. 6), considered as the reference value for 
within-group statistical comparisons. Then, in each group D% data were averaged per 
stimulation on the basis of time elapsed from the first stimulation following the treatment and 
then plotted as mean D% ± S.D. (see figure legends). For significant changes, maximum 
mean D% and the related mean absolute values are reported. The time course of MDA 
parameters was analysed within each group using a one-way analysis of variance (ANOVA) 
versus baseline values, with a following Bonferroni post-hoc test. Between-treatments 
comparisons were made by two-way ANOVA, since the occurrence of drug-induced 
suppression of paroxysmal response did not allow the use of a repeated measures ANOVA, 
and by Bonferroni post-hoc test. This analysis was employed to assess the effect of time of 
stimulus (as within-group factor), treatment (as between-groups factor) and their interaction 
 21 
 
on MDA parameters. Differences were considered statistically significant when P was less 
than 0.05. 
Pilocarpine model 
Behavioural procedures 
The acute pilocarpine model was used to induce seizures by well-established procedures 
(Cuellar-Herrera et al., 2010; Falenski et al., 2009; Mello et al., 1993). Briefly, adult male 
Wistar rats (weight 260–300 g) were administered with methyl-scopolamine (1 mg/kg, i.p.) 
30 minutes before pilocarpine treatment to minimize peripheral, parasympathetic effects. 
Pilocarpine (350 mg/kg, i.p.) was then given to induce seizures, whose onset typically 
occurred within 20 to 40 min after pilocarpine injection. Behavioural seizures were monitored 
for 120 minutes by video recording, scored off-line every 10 minutes and confirmed by an 
experimenter blinded to the experimental treatment. A seizure severity score (0–5) was 
assigned according to a modified Racine scale, appropriate for the acute pilocarpine model 
(Jones et al., 2012), with regard to the animals’ maximal behavioural response (as indicated in 
the table 1). The time course of these scores was used as a qualitative measurement of the 
severity of the convulsions the ‘‘behavioural scoring’’. On the whole, the following 
parameters were assessed during the observation: (1) behavioural scoring; (2) latency to the 
first seizure state; (3) percentage of animals presenting severe generalized seizures, i.e. tonic-
clonic seizures; (4) mortality rate within 24 h, as assessed by Cuellar-Herrera et al. (2010). 
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Tab. 1. Severity scoring scale for acute pilocarpine-induced seizures (Jones et al., 2012). 
Statistical Analysis 
Results of total behavioural changes produced by pilocarpine injection were compared using 
the non-parametric Kruskal–Wallis ANOVA, applied for the ordinal variables (total seizure 
severity scored with the Racine scale), followed by a post-hoc Dunn’s test. The differences 
between behavioural scores per time point in control and treated groups were statistically 
analysed using the Fisher’s exact test. Furthermore, latencies to first seizure state (in minutes) 
were analysed using a parametric one-way ANOVA for within- and between-treatments 
differences, followed by a Bonferroni post-hoc test for multiple comparisons. Lastly, the 
percentage of animals with severe generalized seizures and mortality rate were analysed using 
the χ2 test. Data are presented as mean ± S.D. or percentages. Values were considered 
statistically significant when P<0.05. 
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EXPERIMENT 1: CB AND NO-ACTIVE DRUGS ASSESSMENT 
MDA model 
Drug treatment 
All drugs were purchased from Sigma Chemical Co. (Sigma, St. Louis, MO, USA), with the 
exception of AM251, purchased from AbCam (Cambridge, UK), and of AM630 and ODQ 
(1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one) from Tocris Bioscience (Bristol, UK). All 
drugs were dissolved in the same vehicle for each animal (15% of DMSO in saline solution).  
In experiment 1, several groups of rats were taken into consideration. Control and vehicle-
treated groups were studied for a period of at least 250 minutes in order to verify possible lack 
of response or modifications of MDA parameters due to the repetitive stimulations or to the 
vehicle administration. Responses of vehicle-treated rats were not different in comparison 
with controls.  
Cannabinoid drugs used in experiment 1 were as follows: WIN, a CBR non selective agonist; 
AM251, a CB1R antagonist, and AM630, a CB2R antagonist. Whereas, the NO-active 
substances applied were: 7-nitroindazole (hereafter 7NI), preferential nNOS inhibitor; 
arginine (hereafter, ARG), precursor of NO synthesis, and 1H-[1,2,4]oxadiazole[4,3-
a]quinoxalin-1-one (hereafter named ODQ), specific sGC antagonist.  
Firstly, groups were administered with single treatments of cannabinoids at the following 
doses: WIN in a range from 1 to 21 mg/kg, i.p. and AM630 at 2 mg/kg (n=6 per group). Also, 
single administration of 7NI were injected at increasing doses from 20 to 50 mg/kg i.p. per 
group (n=10 each). Then, co-treatment experiments between drugs at effective doses were 
performed to assess putative interactions in the following groups: AM630-WIN, ODQ-WIN 
and ARG-WIN groups (n=6 per group, with ODQ injected at 10 mg/kg and ARG at 1 g/kg). 
Furthermore, a co-treatment was administered with subeffective doses of 7NI  and WIN (20 
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and 5 mg/kg, i.p. respectively) and indicated as 7NI-WIN group (n=10 rats). Lastly, the 
injection of AM251 (1 mg/kg, i.p.) was performed before subeffective doses of 7NI and WIN 
and indicated as AM251-7NI–WIN group (n=8 rats) to evaluate CB1 receptors influence on 
the interaction. All treatment dosages were based on previous studies and pilot experiments 
(García-Gutiérrez et al., 2012; Rizzo et al., 2009; Sardo et al., 2008; 2006; Wallace et al., 
2001). Each pharmacological treatment was performed after five consecutive stable MDA 
responses (baseline period) and the subsequent observation period lasted up to 180 minutes 
after the injection of the last drug. In the co-treatment groups, due to different 
pharmacokinetic profiles of the drugs administered, an interval was interposed between 
administrations so as to allow coincident actions (all drugs 30 min from WIN injection and 
AM251 50 min before 7NI-WIN). 
Pilocarpine model 
Drug treatment 
Behavioural procedures in experiment 1 comprised 10 rats per group. Control and vehicle-
treated groups were studied for a period of 120 minutes in order to verify possible 
modifications of behavioural seizures due to vehicle administration. In each remaining group, 
prior to behavioural seizure protocol, animals received the same individual doses of 7NI and 
WIN, as in MDA model. Single pharmacological treatment with 7NI or WIN at different 
doses was performed 15 minute before scopolamine administration (Jones et al., 2012). 
Control tests to assess the effects of AM251 as an antagonist of WIN action (AM-WIN group) 
were performed administering AM251 (1 mg/kg, i.p.) 40 min before an effective dose of WIN 
(10 mg/kg). In the group indicated as 7NI-WIN, animals were co-treated with sub-effective 
doses of 7NI (20 mg/kg, i.p) and WIN (1 mg/kg, i.p.). WIN was injected 15 minute before 
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scopolamine at distinct times from 7NI on the basis of kinetics of action (7NI 20 min before 
WIN injection). As for AM251-7NI–WIN group, AM251 (1 mg/kg, i.p.) was added to 7NI–
WIN administration protocol, with the AM251 injected 40 min before WIN. To exclude the 
effect of vehicle, co-treatment experiments were preliminary conducted administering the 
vehicles before WIN.  
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EXPERIMENT 2: TRPV1 ROLE IN CANNABINOID EFFECTS 
MDA model  
 Drug treatment 
All drugs were purchased as above, whereas capsaicin (CAP) and capsazepine (CPZ) were 
purchased from ABCam (Cambridge, UK). This experiment took into consideration groups of 
animals, comprising 6 rats each. In the single-treated groups the animals received CAP in a 
range from 1 to 10 mg/kg, i.p., respectively per group, and CPZ from 0.5 to 2 mg/kg, i.p. 
Then, co-treatments were performed in the following groups: a co-administration with CAP 
and WIN (both at 10 mg/kg, i.p), a co-administration with CPZ and WIN (2 mg/kg and 10 
mg/kg, i.p, respectively) and a co-administration with CPZ and WIN (2 mg/kg and 5 mg/kg, 
i.p, respectively). Dosages chosen for WIN co-administration are described above (see 
Experiment 1), while TRPV1-active drugs were applied on the basis of previous findings (Jia 
et al., 2015). All drugs were dissolved in the same final vehicle volume for each animal (15% 
of DMSO in saline solution). In the co-treated groups, due to different pharmacokinetic 
profiles of the drugs administered, an interval was interposed between administrations so as to 
allow coincident actions. In detail, the CAP-WIN group was administered with CAP 30 min 
before WIN injection, and the CPZ-WIN groups with CPZ 30 min before receiving treatment 
with WIN at 10 or 5 mg/kg.  
Lastly, pilot experiments were conducted administering 7NI, CAP and WIN (at 50, 10 and 10  
mg/kg, respectively), and ARG, CAP and WIN (1g/kg for ARG and 10 mg/kg for the other 
two). In these 2 groups (7NI-CAP-WIN and ARG-CAP-WIN groups), 7NI or ARG were 
injected respectively 10 min before CAP and 40 min before WIN injection.  
For all the experiments, each pharmacological treatment was performed only after five 
consecutive stable MDA responses (baseline period) and the subsequent observation period 
 27 
 
lasted 180 minutes after the drug injection in the groups treated with single drugs or after the 
last drug administration for all co-treated groups. 
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RESULTS 
EXPERIMENT 1 
MDA model 
Control and vehicle-treated groups  
In untreated controls and vehicle-treated groups, repetitive AB stimulations always induced a 
MDA response whose parameters were not altered along the experimental observation period 
(Tab. 2, fig. 6 and 7 a). 
 
Time of 
stimulus 
CTR WIN      
10 mg/kg 
WIN      
5 mg/kg 
WIN      
1 mg/kg 
AM630-
WIN 
10 100 100 100 100 83 
20 100 33** 83 100 67 
30 100 50* 83 100 0** 
40 100 50* 67 100 16** 
50 100 33** 100 100 16** 
60 100 83 100 100 50* 
70 100 83 100 90 67 
80 100 67 100 100 83 
90 100 67 100 100 83 
100 100 67 100 100 50* 
110 100 67 100 100 83 
120 100 67 100 100 100 
Tab. 2. Summary of the percentage (%) of MDA responses per group, considering the first 120 min of 
stimulation. The reported significances are derived from a χ2 analysis. (*) P < 0.05. (**) P < 0.01 
versus vehicle-treated controls (CTR). 
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Fig. 5. Histological hippocampal section: 1.7mm (left) and 5.4mm (right) anterior to the interaural 
line (photomicrograph, 40x; Nissl-Cresyl Violet staining). The green dot shows a recording site in the 
dentate gyrus (DG) marked through iontophoretic Fast Green injection. 
 
 
Fig. 6. Time course of MDA parameters in vehicle-treated controls. Each value represents the mean 
D% of baseline ±S.D. 
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Fig. 7. Representative MDA responses exhibiting: a) vehicle-treated paroxysmal discharge; b) 
treatment-induced decrease in paroxysmal discharge; c) treatment-induced blockade of paroxysmal 
discharge; d) treatment-induced increase in paroxysmal discharge. Example traces are taken from the 
same animal. 
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Effect of single doses of WIN and of AM630 on % protection and MDA 
parameters 
A within-treatment analysis on MDA responses, after WIN administration at different 
dosages, highlighted a clear efficacy (% protection = 27, 77%) exerted by WIN at 10 mg/kg 
(Fig. 8 a). The amount of non-responses was significant up to 50
th
 min with a maximal effect 
at 20
th
 and 50
th
 min when only 33.33% of animals responded to AB stimulation (χ2= 6.00, DF 
= 1, P = 0.0014; tab. 2 and represented in fig. 7 c). The whole period of protection last up to 
140
th
 min. On the other hand, WIN 5 mg/kg showed a non-significant protection in a fewer 
number of stimulations (20–40th min; tab. 2). Then, analyses were conducted on WIN effect 
on MDA parameters. In the group treated with WIN at 10 mg/kg, a within-treatment ANOVA 
revealed an increase in the time of onset (F(18,65) = 2.07, P = 0.017; fig. 8 b; as represented in 
fig. 7 b). Post-hoc analysis showed a significant effect from 20
th
 to 130
th
 min, with a 
maximum effect at 60
th
 min (D% = +61.78 ± 17.56). Moreover, a reduction of MDA duration 
was evident (F(18,65) = 3.79, P < 0.0001), starting from 20
th
 to 110
th
 min with a maximum 
effect at 60
th
 min (D% = −69.72 ± 32.23). Similarly, WIN 10 mg/kg induced a reduction in 
the AD duration (F(18,65) = 2.88, P < 0.0001), from 20
th
 to 110
th
 min, with a maximum effect at 
60
th
 min (D% = −71.68 ± 32.88). As for the treatment with WIN at 5 and 1 mg/kg, a within-
treatment ANOVA did not outline any statistical differences. Between-treatments 
comparisons of WIN 10 mg/kg versus both WIN at 5 mg/kg and controls confirmed that 
significant differences were found for all parameters. Indeed, WIN at 10 mg/kg showed 
significant main effects versus WIN at 5 mg/kg of stimulus time (Onset: F(17,180) = 7.721, 
P<0.0001; MDA: F(17,180) = 4.193, P<0.0001 and AD: F(17,180) = 3.742, P<0.0001), treatment 
(Onset: F(17,180) = 475.7, P< 0.0001; MDA: F(17,180) = 88.81, P<0.0001 and AD: F(17,180) = 
34.12, P<0.0001) and interaction (Onset: F(17,180)= 4.205, P<0.0001; MDA: F(17,180)= 2.239, 
P=0.0047 and AD: F(17,180) =1.747, P=0.0038). Between-treatments post-hoc results showed 
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an increase in the onset time in WIN at 10 mg/kg and subsequent reduction in MDA and AD 
durations for P<0.05 (as indicated in fig. 8 b).  
 
Fig. 8. (a) Effects of WIN at 10, 5 and 1 mg/kg on the % of MDA protection. (*) for the experimental 
groups that presented significant differences at least in one stimulation time point, versus controls (for 
P<0.05). (b) Time course of MDA parameters during the 18 progressive stimuli. Each value represents 
the mean of D% ± S.D. of each treatment per stimulus versus baseline values (● WIN 10 mg/kg, ● 
WIN 5 mg/kg, ● WIN 1 mg/kg). Within-treatment statistically significant D% of WIN at 10 mg/kg is 
indicated as (*) for P<0.05 vs baseline values. Between-treatments significance of WIN at 10 mg/kg 
was indicated as (
◦
) for P<0.05 versus WIN at 5 mg/kg. 
The co-treatment of AM630 and WIN at maximal dose enhanced WIN-induced reduction in 
the % of responses to AB stimulation, as described henceforth. In particular, a within-
treatment analysis on AM630-WIN group displayed significant changes on the percentage of 
responses to AB stimulation. Indeed, data showed a marked decrease from 30
th
 to 60
th
 min 
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and from 100
th
 to 110
th
 min, with a maximal effect at 30
th
 min when no animals exhibited any 
MDA response (χ2= 12.000, DF=1, P=0.0005). A further analysis on the % of responses in 
AM630-WIN group showed significant differences with respect to WIN alone: in fact, the co-
treatment continuously reduced the % of responses from 30
th
 to 70
th
 min, with a significant 
decrease at 3
rd
 stimulus (maximal reduction observed: 50%, χ2=4.000, DF=1, P=0.0455), with 
respect to WIN alone (Tab .2). The assessment of AM630 alone proved to be ineffective on 
MDA responses since AB stimulations were always followed by DG activation in the 
observation period. The pre-treatment with AM630 in WIN-treated animals enhanced WIN 
effect on MDA parameters. In particular, a within-treatment analysis revealed that AM630-
WIN co-treatment increased the mean onset from 60
th
 to 110
th
 min, with a maximum effect of 
+86.05 ± 10.22% at 70
th
 min (F(15,55)= 10.754, P= 0.0003). Moreover, a reduction of MDA 
duration was evident from 60
th
 to 120
th
 min, with a maximum effect of -85.49 ± 3.92% at 70
th
 
min (F(16,51)= 6.212, P= 0.0001). Similarly, the co-treatment induced a reduction in the AD 
duration from 60
th
 to 120
th
 min, with a maximum effect of +87.04 ± 3.20% at 70
th
 min 
(F(15,55)= 5.994, P= 0.0003). Lastly, a statistical comparison between the effects of AM630-
WIN versus WIN alone showed a significant increase of the time of onset from 60
th
 to 120
th
 
min in the co-treated group, with the maximal effect at 110
th
 of +80.56 (from –8.76% ± 15.2 
to +71.8% ± 13.9; F(1,6)= 59.236 and P= 0.0003;). The same analysis for MDA and AD 
durations did not reveal significant differences (Fig. 9).    
The possible variations of MDA parameters was also evaluated in the group treated with 
AM630 alone. It was found that the treatment did not significantly modify MDA parameters, 
if compared to baseline period. Also, no statistical significance resulted from a between-
treatments analysis comparing MDA parameters in AM630 versus vehicle-treated and control 
group. Furthermore, a statistical analysis was performed to compare the effects of AM630 
versus WIN administration at the highest dose used on MDA parameters. Significant 
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differences did not emerge in the time of onset whereas a significant reduction of the mean 
MDA duration was found in WIN group from 40
th
 to 100
th
 min, with a maximum effect at 
60
th
 min of -54.79 (from -15.6 ± 23.82% to -70.39 ± 13.70%; F(1,9)= 10.033 and P= 0.0114;), 
compared to AM630. Lastly, it was shown a significant decrease of AD duration in WIN 
group from 40
th
 to 100
th
 min, with a maximum effect at 90
th
 min of -85.13 (from +17.65 ± 
42.51% to -67.48 ± 10.86%; F(16,51)= 13.662 and P= 0.007), compared to AM630 (Fig. 9). 
 
Fig. 9. Effects of AM630 at 2 mg/kg and AM630-WIN on the time course of MDA parameters during 
the 12 progressive stimuli. Each value represents the mean of D% of each treatment (■ AM630, ▲ 
AM630-WIN) per stimulus versus baseline values. At 30
th
 min in AM630-WIN group no animal 
responded to stimulation, therefore this value is not reported in figure. Within-treatment statistically 
significant D% of AM630-WIN is indicated for P < 0.05 (*) vs baseline values. Between-treatments 
significance of AM630-WIN is indicated for P < 0.05 (°) vs WIN alone.  
Effect of single doses of 7NI on % protection and MDA parameters 
Within-treatment analysis on the group treated with 7NI 50 mg/kg displayed significant 
changes in the percentage of responses to AB stimulation. Indeed, data showed a marked 
decrease from 40
th
 to 150
th 
min, with a maximal effect at 100
th
 and 120
th
 min when 40% of 
animals were protected from seizures induced in DG by AB stimulation (χ2=5.0, DF=1, 
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P=0.025). In contrast, the treatment with 7NI 35 mg/kg did not show any statistically 
significant percentage of protection, though MDA was not elicited in the 10% of animals only 
at 20
th
 min, and in some stimulations after 110
th
 min. Lastly, the treatment with 7NI 20 mg/kg 
resulted clearly inefficacious since all animals in this group always responded to all 
stimulations (Tab. 3 and fig. 10 a). 
 
Time of 
stimulus 
7NI        
50 mg/kg 
7NI        
35 mg/kg 
7NI        
20 mg/kg 
7NI-
WIN 
AM251-
7NI-
WIN 
ARG-
WIN 
ODQ-
WIN 
10 100 100 100 50** 100 100 33* 
20 100 90 100 20*** 100 83 16** 
30 100 100 100 20*** 100 66 16** 
40 90 100 100 20*** 100 66 16** 
50 70 100 100 40** 90 66 16** 
60 70 100 100 60* 90 83 33* 
70 80 100 100 60* 100 100 16** 
80 70 100 100 80 100 100 16** 
90 70 100 100 70 100 83 33* 
100 60* 100 100 100 100 83 16** 
110 70 90 100 80 100 83 33* 
120 60*  90 100 100 100 100 50* 
Tab. 3. Summary of the percentage (%) of MDA responses per group, considering the first 120 min of 
stimulation. The reported significances are derived from a χ2 analysis. (*) P<0.05 and (**) P<0.01 
versus controls (CTR). 
7NI at several doses differently influenced MDA parameters, when compared to baseline 
values. In particular, in the group treated with 7NI at 50 mg/kg a within-treatment ANOVA 
showed a significant reduction of MDA duration (F(18,156) = 2.13; P= 0.0076) with a maximum 
effect at 110
th
 min (D%: -53.00% ± 22.76) and of the AD duration (F(18,156) = 1.798; P= 0.03) 
maximum at 120
th
 min (D%:-42.88 ± 24.33). Whereas, only a non-significant increase in the 
time of the onset was evidenced. The same analysis for 7NI at 35 and 20 mg/kg for onset, 
MDA and AD durations did not reveal noticeable statistical differences. Also, between-
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treatments comparison on MDA parameters of 7NI at 50 mg/kg showed differences versus 
7NI at 35 and 20 mg/kg in stimulus time (Onset: F(17,486)= 1.933, P=0.0139; MDA: F(17,486)= 
1.387, P<0.0001 and AD: F(17,486)= 1.097, P=0.3531), treatment (Onset: F(17,486)= 42.12, P< 
0.0001; MDA: F(17,486)= 37.12, P= 0.1375 and AD: F(17,486)= 32.08, P<0.0001) and interaction 
(Onset: F(17,486)=0,8714, P=0.6786; MDA: F(17,486)= 0.9956, P=0.4779 and AD: F(17,486)= 
0.8701, P=0.6807). Post-hoc results outlined a reduction in MDA and AD durations of 7NI 50 
for P<0.05 (as indicated in fig. 10 b). 
 
Fig. 10. (a) Effects of 7NI at 50, 35 and 20 mg/kg on the % of MDA protection. (*) for the 
experimental groups that presented significant differences at least in one stimulation time point, versus 
controls (for P<0.05). (b) Time course of MDA parameters during the 18 progressive stimuli. Each 
value represents the mean of D% ± S.D. of each treatment per stimulus versus baseline values (● 7NI 
50 mg/kg, ■ 7NI 35 mg/kg, ▲ 7NI 20 mg/kg). Within-treatment statistically significant D% of 7NI at 
50 mg/kg is indicated as (*) for P<0.05 vs baseline values. Between-treatments significance of 7NI at 
50 mg/kg was indicated as (◦) for P<0.05 versus 7NI at 35 mg/kg. 
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Effect of 7NI and ARG on cannabinoid activity 
Following single drug treatments, 7NI and WIN were co-administered at doses proved to be 
singularly ineffective for protection from electrically-induced seizures, i.e. 20 mg/kg for 7NI 
and 5 mg/kg for WIN (Tab. 3 and fig. 11 a). No changes in MDA responses were found after 
pretreatment with 7NI up to the time of WIN administration. The χ2-test performed on the 
number of responding animals after 7NI–WIN co-treatment revealed a strong protection from 
seizures starting 10 min after the administration of the second drug and lasting up to 70 min, 
with a maximum effect between 20
th
 and 40
th
 min when only 20% of animals responded to the 
stimulation (χ2=13.33, DF=1, P=0.0003). This result showed a significant 7NI–WIN-induced 
enhancement of protection from epileptic discharges, when compared to the outcomes of 
WIN at 5 mg/kg; indeed, the maximal D% of protection was observed at 20
th
 and 30
th
 min 
versus WIN at 5 mg/kg (D%:+70%, χ2=9.899, DF=1, P=0.0017). The observed effect was 
abolished when animals were pretreated with the CB1 antagonist AM251 before 7NI and WIN 
injections. MDA response were almost always elicited since only 10% of animals did not 
respond for a short-time interval between only at 50
th
 and 60
th
 min after WIN administration. 
Vehicle tests for co-treatment did not show any change in WIN 5 mg/kg single action. 
As for MDA parameters, the effects of co-treatment with WIN (5 mg/Kg) and 7NI (20 
mg/Kg) was analysed for within-treatment statistical differences. In particular, the time of 
onset significantly increased with respect to baseline values (F(18,139) = 1.995, P=0.0147); 
post-hoc Bonferroni test showed a significant increase with maximum effect at 20
th
 min 
(D%:+47.10 ± 4.78). Additionally, a within-treatment decrease in MDA and AD durations 
emerged (respectively: F(18,139) = 4.214, P<0.0001 and F(18,139) = 4.395, P<0.0001). In 
particular, post-hoc comparisons highlighted significant differences from 10
th
 to 130
th
 min 
and at 160
th
 and 170
th
 min, reaching a maximum at 50
th
 min (respectively: D%: -60.15 ± 
16.85% and D%: -88.79 ± 2.29%). As for between-treatments comparisons of 7NI-WIN 
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versus WIN at 5mg/kg, a two-way ANOVA for the time of onset revealed significant main 
effects of stimulus time (F(17,252) = 2.31, P =0.0028), treatment (F(17,252) = 22.32, P<0.0001), 
but not their interaction (F(17,252) = 1.47, P=0.104). The same analysis performed on MDA 
showed significant main effects of stimulus time (F(17,252) = 2.36, P=0.0022) and treatment 
(F(17,252) = 81.91, P <0.0001), but not their interaction (F(17,252) = 0.57; P=0.90). Regarding AD 
durations a significant main effect emerged for stimulus time (F(17,252) = 3.15, P<0.0001), 
treatment (F(17,252) = 92.3, P <0.0001) but not their interaction (F(17,252) = 0.96, P=0.49). 
Bonferroni post-hoc test revealed that 7NI-WIN administration significantly increased onset 
time versus WIN at 5 mg/kg at 10
th
 and 20
th
 min, and reduced MDA and AD duration 
respectively at 50
th
 and 60
th
 min and from 30
th
 to 70
th
 min (P<0.05, fig. 11 b).  
As observed in the analysis of % MDA protection, the presence of AM251 reduced the 
antiepileptic effects of 7NI-WIN co-treatment. In detail, within-treatment ANOVA on 
AM251-7NI-WIN showed a significant increase in onset time (F(18,149) = 2.30, P=0.0037) and 
a reduction of MDA and AD durations (F(18,149) = 0.30, P<0.0001and F(18,149) = 0.33, P< 
0.0001), reaching a maximum effect at 120
th
 min (onset D%: 20.72 ±18.14; MDA D%: -
27.03± 50.95 and AD D%:-25.30± 70.38). Though, in the onset time between-treatments 
comparison versus 7NI-WIN co-treatment alone showed significant main effects of stimulus 
time (F(17,288) = 2.66, P=0.0005), but not of treatment (F(17,288) = 0.07, P=3.30) and their 
interaction (F(17,288) = 1.14, P=0.31). This analysis conducted on MDA and AD durations of 
AM251-7NI-WIN group with respect to 7NI-WIN highlighted significant main effects of 
stimulus time (MDA: F(17,288) = 1.91, P<0.0001 and AD: F(17,288) = 3.17, P<0.0001) and 
treatment (MDA: F(17,288) = 177.8, P <0.0001 and AD: F(17,288) = 199.2, P<0.0001), but not 
their interaction (MDA: F(17,288) = 1.40, P=0.13 and AD: F(17,288) = 1.29, P=0.19; fig. 11 b). 
Indeed, between-treatments post-hoc tests revealed significant reductions of MDA (at 10
th
, 
30
th
 and 60
th
 min, and from 110
th
 to 130
th
 min) and of AD durations (at 10
th
, 30
th
,50
th
 and 60
th
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min, from 110
th
 to 130
th
 min and at 170
th
 min)  in 7NI-WIN group compared to AM251-7NI-
WIN (for P<0.05) , as indicated in fig. 11 b. 
 
Fig. 11. (a) The bar graph shows the % of protection for WIN (5 mg/kg), alone and co-treated with 
7NI (20 mg/kg) or with both 7NI and AM251 (1 mg/kg). (*) for the experimental groups that 
presented significant differences at least in one stimulation time point, versus controls (for P<0.05). 
(b) Time course of MDA parameters during the 18 progressive stimuli. Each value represents the 
mean of D% ± S.D. of each treatment per stimulus versus baseline values (■ 7NI-WIN, ■ AM251-
7NI-WIN, ● WIN 5 mg/kg). Within-treatment statistically significant D% of 7NI-WIN is indicated as 
(*) for P<0.05 vs baseline values. Between-treatments significance of 7NI-WIN group is shown as (#) 
for P<0.05 versus WIN at 5 mg/kg;  as (°) for P<0.05 versus AM251-7NI-WIN and as (§) versus both 
WIN at 5 mg/kg and AM251-7NI-WIN group. 
Furthermore, ARG, the NO precursor, was administered before WIN at 10 mg/kg to evaluate 
the effects of activating nitrergic production. The % of protection from seizures (15%) was 
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reduced compared to WIN alone, and only a non-significant reduction of responses was 
observed between 30
th
 and 50
th
 min (Tab. 3 and fig. 12 a). Within-treatment analyses on 
MDA parameters showed no significant effects of ARG-WIN versus baseline values. Also, 
between-treatments comparison with WIN alone on MDA parameters highlighted significant 
main effects of treatment (Onset: F(17,180) = 67.64, P<0.0001; MDA: F(17,180) = 41.36, P<0.0001 
and AD: F(17,180) = 29.15, P<0.0001) and interaction (Onset: F(17,180) =2.54, P=0.012; MDA: 
F(17,180) = 2.82, P= 0.0003 and AD: F(17,180) =2.67, P=0.0006), but not of stimulus time (Onset: 
F(17,180) = 1.9, P=0.002; MDA: F(17,180) = 1.58, P=0.07 and AD: F(17,180) = 1.59, P=0.069). Post-
hoc results show a reduction in the onset time in ARG-WIN from 30
th
 to 60
th
 min versus WIN 
(P<0.05) and an increase in MDA and AD durations from 40
th
 to 60
th
 min (Fig. 12 b).  
Lastly, WIN at the highest dose was co-administered with ODQ to assess the implication of 
sGC in cannabinoid effects. A within-treatment χ2 test revealed that in ODQ-WIN group 75% 
of the animals were protected from seizures from 10
th
 to 120
th
 min, with a maximal effect of 
−83.3% recorded in the stimulations where the number of responses was 1 (χ2= 8.571, DF = 
1, P<0.01). A further comparison of the % responses in ODQ-WIN group with respect to 
WIN alone showed significantly reduced responsiveness at 10
th
, 70
th
 and 80
th
 min (the 
reduction observed was respectively: 66.6%; χ2 = 6.000, DF = 1, P=0.0143 at 10th min; χ2 = 
5.33, DF = 1, P=0.02 at 70
th
 and 80
th
 min; tab. 3). The analysis on MDA parameters revealed 
that the co-treatment did not induce any significant differences in the onset parameter when 
compared to baseline period, whereas a reduction of MDA duration was found for the entire 
period of the observation, with a maximum at 90
th
 min (D%: -75.18% ± 22.10; F(15,19) = 1.653 
and P=0.0053); the co-administration also reduced AD duration for 120 min, with a maximum 
effect at 90
th
 min (D%:-80.40% ± 14.1; F(15,19) = 1.252 and P=0.0130). Due to the massive 
ODQ-WIN-induced reduction of responses to stimulation (n= 1 at various stimulation time 
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points), a between-treatments analysis to compare ODQ-WIN effects to WIN administration 
alone on the MDA parameters did not allow any statistical comparisons. 
 
Fig. 12. (a)  The bar graph shows the % of protection for WIN (10 mg/kg), alone and co-treated with 
ARG. (*) for the experimental groups that presented significant differences at least in one stimulation 
time point, versus controls (for P<0.05). (b) Time course of MDA parameters during the 18 
progressive stimuli. Each value represents the mean of D% ± S.D. of each treatment per stimulus 
versus baseline values (■ ARG-WIN, ● WIN 10 mg/kg). Between-treatments significance of WIN at 
10 mg/kg  was indicated as (°) for P < 0.05 versus ARG-WIN. 
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Pilocarpine model 
Control and vehicle-treated groups  
Both control and vehicle-treated groups showed severe generalized seizures and no survival 
was recorded after the experimental sessions (Tab. 4 and fig. 13). 
 
Group Severe seizures % Mortality (24h) % 
CTR 100 100 
WIN 10 mg/kg 0*** 0*** 
WIN 5 mg/kg 0*** 20** 
WIN 1 mg/kg 90 80 
7NI 50 mg/kg 0*** 50** 
7NI 35 mg/kg 0*** 60* 
7NI 20 mg/kg 70 80 
7NI-WIN 0*** 50** 
AM251-7NI-WIN 80 80 
Tab. 4. Summary of the percentage (%) of severe seizures and mortality (24 h) in the pilocarpine 
model per group. A χ2 test was performed for statistical comparisons. (*) for P<0.05; (**) P<0.01; 
(***) P<0.001 versus controls (CTR). Doses for 7NI–WIN and AM251-7NI–WIN groups are 
indicated in the text. 
 
Fig. 13. Examples of behavioural symptoms of increasing severity, showed by vehicle-treated rat after 
pilocarpine injection.  
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Effect of single doses of  WIN and 7NI on % of severe seizures and mortality 
A χ2 analysis performed for the percentage of animals with severe seizures in WIN-treated 
groups showed a similar reduction for both WIN at 10 and 5 mg/kg (0%, P<0.001) with 
respect to controls, whereas WIN 1 mg/kg did not show statistical differences (severe 
seizures: 90%; tab. 4). In addition, statistical comparisons of mortality rates revealed that 
WIN 10 mg/kg dampened percentages of mortality (all survived, P<0.001) versus controls, as 
well as WIN 5 mg/kg (20% mortality, P<0.01), while WIN 1 mg/kg did not significantly 
modify this parameter (mortality rate: 80%). Furthermore, an evaluation of CB1 receptors role 
on anticonvulsant effect of WIN was carried out administering the CB1R antagonist AM251 
before the most effective dose of WIN (10 mg/kg). With this approach, WIN effects were 
impaired and % of severe seizures went up (90%, P=0.0001) as well as mortality (60%, 
P=0.0034) versus WIN 10 mg/kg group.  
As for 7NI effect on the percentage of severe seizures, after 7NI at both 50 and 35 mg/kg the 
amount of animals reaching score 5 seizures was dropped with respect to controls (0%, 
P<0.001), while after 7NI at 20 mg/kg significant changes were not observed (severe seizures: 
70%). Similar analyses performed on the mortality rate revealed that only 7NI at both 50 and 
35 mg/kg significantly reduced the percentages of dead animals within 24h from the 
experimental session. 7NI at 50 mg/kg showed 50% mortality (P<0.01) and 7NI at 35 mg/kg 
60% mortality (P<0.05), respectively analysed versus the 100% mortality of controls.  
Effect of single doses of WIN and 7NI on behavioural scoring and latency to the 
first seizure state  
Results of a Kruskal–Wallis test, performed on behavioural scoring for WIN-treated groups, 
including ‘‘treatment’’ as the between-groups factor, revealed statistical differences between 
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groups (P=0.0003). Post-hoc analysis highlighted significantly reduced behavioural 
symptoms in WIN 10 mg/kg (total scoring of 0.65±0.75, P<0.0001) and 5 mg/kg (1.3±0.34, 
P<0.05) groups with respect to controls, but behavioural scoring was not significantly 
different in WIN 1 mg/kg versus controls (2.09±0.4; fig. 14 a). Significant changes were 
found in latencies of pilocarpine-induced behavioural alterations for WIN groups with respect 
to controls (F(3,36) = 3.764, P=0.019).  
 
Fig. 14. (a) Effects of WIN (10, 5, 1 mg/kg) on behavioural scores during the 120 min following the 
administration of pilocarpine. Fisher’s exact test per time point evidenced significant differences as 
described hereafter. (°) for P<0.05 of WIN (10 mg/kg) versus controls (CTR); (*) for P<0.05 of both 
WIN at 10 and 5 mg/kg respectively versus CTR. (b) Latency in min to first seizure state. A within-
treatment one-way ANOVA evidenced statistically significant differences for (*) P<0.05 versus 
control group. All values are presented as mean ± S.D. 
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In particular, post-hoc comparisons highlighted a marked increase only in the latency of WIN 
at 10 mg/kg versus controls (from 21.88±4.08 of CTR to 30.26±10.73 min of WIN 10 mg/kg, 
P<0.05; fig.  14 b). As for an aspect considered in other research (Wallace et al., 2003), at the 
maximal used dose of WIN (10 mg/kg), animals showed mild sedation, especially in the last 
30 min of observation, without any locomotor alterations. On the other hand, with WIN at 5 
mg/kg rats were not evidently affected and alert enough to be able to move freely. WIN 1 
mg/kg did not induce any aversive signs. 
 
Fig. 15. (a) Effects of 7NI (20, 35 and 50 mg/kg) on behavioural scores during the 120 min following 
the administration of pilocarpine. Fisher’s exact test per time point evidenced significant differences 
as described hereafter. (°) for P<0.05 of 7NI (50 mg/kg) versus controls (CTR); (*) for P<0.05 of both 
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7NI at 50 and 35 mg/kg, respectively versus CTR. (b) Effect of 7NI at different doses on latency in 
min to first seizure state. All values are presented as mean ± S.D. 
The same analysis on the effect of 7NI on total behavioural score showed significant 
differences among the experimental groups (P=0.0004). Dunn’s post-hoc analysis highlighted 
a significantly reduced behavioural score in 7NI at both 50 mg/kg (total scoring of 0.64±0.67, 
P<0.0001) and 35 mg/kg (0.66±0.51, P<0.001), respectively versus controls (total scoring of 
2.64±0.43); behavioural scoring of rats treated with 7NI 20 mg/kg was non-statistically 
different than controls (Fig. 15 a). Non-significant changes were found in the latency of 
pilocarpine-induced behavioural alterations for all 7NI groups with respect to controls (Fig. 
15 b). 
As for the involvement of CB1 receptors in WIN effects, when AM251 was administered 
before the highest dose of WIN, the behavioural scoring revealed statistical differences 
between groups (P=0.0007), with an increase in total scoring of 1.34±0.5 for AM251-WIN 
group with respect to WIN 10 mg/kg alone. Fisher’s exact test showed that the effect of 
AM251 was maintained up to 110
th
  min (for P<0.05). As regards the analysis of latency, a 
one-way ANOVA revealed an early effect of AM251 since significant differences emerged 
between AM251-WIN, WIN 10 mg/kg and control groups (F(2,27) =8.65; P=0.012). In detail, 
post-hoc analysis highlighted that latency of AM251-WIN group was significantly decreased 
compared to WIN 10 mg/kg (from 30.26±10.73 of WIN 10 mg/kg to 17.30±4.21 min of 
AM251-WIN, P<0.001).  
Effect of 7NI–WIN and AM251-7NI–WIN groups on % severe seizures and 
mortality 
The 7NI–WIN co-treatment respectively with 20 mg/kg and 1 mg/kg, singularly ineffective 
doses, did not elicit any severe seizures (0%, P<0.0001) and decreased the mortality by 50% 
 47 
 
(P<0.01), as shown by χ2-test statistical analysis versus controls (Tab. 4). When animals were 
pretreated with the CB1 antagonist AM251, before 7NI and WIN injections, 7NI–WIN effects 
were impaired and % of severe seizures went up to 80% (P=0.0003) as well as mortality 
(80%, P=0.022) versus 7NI–WIN group. 
Effect of 7NI–WIN and AM251-7NI–WIN groups on behavioural scoring and 
latency to the first seizure state 
Analysis to evaluate the effect of 7NI–WIN co-treatment revealed statistical differences on 
the behavioural scoring between groups (P=0.0109). Particularly, a post-hoc analysis showed 
a significant reduction of behavioural scores in 7NI–WIN group with respect to WIN alone at 
1 mg/kg (total scoring of 0.8±0.76, P<0.01; fig. 16 a). Whereas, this protective outcome is no 
more obtained when CB1 receptors are antagonized with AM251 (total scoring of 1.77±0.56) 
when compared to 7NI–WIN and WIN 1 mg/kg. The behavioural scoring in AM251-7NI–
WIN appears higher than 7NI–WIN group for the 120-min observation (Fig. 16 a). As for 
analysis of latency, a one-way ANOVA revealed significant differences (F(3,36) = 9.039; 
P=0.0001). In detail, post-hoc analysis outlined that latency of 7NI–WIN group was 
significantly increased compared to WIN 1 mg/kg (from 22.67±3.55 of WIN 1 mg/kg to 
31.95±3.26 min of 7NI–WIN, P<0.001; fig. 16 b). Furthermore, the pretreatment with AM251 
significantly averted 7NI–WIN effects on latency (24.66±7.29 min of AM251-7NI–WIN 
group, P<0.05; fig. 16 b). Vehicle tests for co-treatment did not show any change in WIN 1 
mg/kg single action. Lastly, no WIN-associated side effects were observed in the 7NI–WIN 
co-treatment. 
 48 
 
 
Fig. 16. (a) Behavioural scores during the 120 min following the administration of pilocarpine. 
Results of Fisher’s exact test evidenced significant differences as described. (°) for P<0.05 of 7NI–
WIN versus controls (CTR); (*) for P<0.05 of 7NI–WIN, respectively versus WIN (1 mg/kg) and 
controls; (#) for P<0.05 of 7NI–WIN versus AM251-7NI–WIN. (b) Latency to first seizure state. 
P<0.001 (**) versus control group. A between-treatments analysis was performed for the 7NI–WIN 
group and revealed significant differences indicated with (°) for P<0.05 versus WIN (1 mg/kg) and 
with (#) for P<0.05 versus AM251-7NI–WIN groups. All values are presented as mean ± S.D. 
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EXPERIMENT 2 
MDA model 
 
Time of 
stimulus 
CAP-WIN CPZ-WIN      
5 mg/kg 
CPZ-WIN    
10 mg/kg 
7NI-CAP-WIN ARG-CAP-WIN 
10 100 100 67 67 67 
20 33** 83 33** 33** 50* 
30 83 67 33** 33** 83 
40 83 83 33** 67 83 
50 100 100 33** 67 100 
60 100 100 67 83 100 
70 100 100 50* 83 100 
80 100 100 50* 83 100 
90 100 100 50* 100 100 
100 100 100 50* 100 100 
110 100 100 67 100 100 
120 100 100 67 100 100 
Tab. 5. Summary of the percentage (%) of MDA responses per group, considering the first 120 min of 
stimulation. The reported significances are derived from a χ2 analysis. (*) P<0.05. (**) P<0.01 versus 
controls (CTR). Values for CAP and CPZ at different doses were not included in table since these 
drugs always induced 100% MDA responses. 
Effect of single doses of capsaicin on % of responses and MDA parameters 
The effects of capsaicin were evaluated using distinct doses in separate groups: 1, 5 or 10 
mg/kg i.p. The % of protection was not modified with respect to controls; indeed, all animals 
treated with CAP at different dosages responded to AB stimulation (% protection = 0). 
Furthermore, a within-treatment ANOVA was used to compare possible changes of MDA 
parameters with baseline values. The treatment with CAP at 10 mg/kg induced significant 
differences (MDA duration, F(18,92) = 2.06, P=0.0135; AD duration, F(18,92) = 2.05, P=0.014; 
fig. 17 a). Post-hoc analysis revealed that the time of onset was significantly reduced from 
40
th
 to 140
th
 min with a maximum effect at 110
th
 min (D% = −24.98 ± 22.42), whilst MDA 
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and AD durations were statistically increased from 20
th
  to 140
th
 stimulation with a maximum 
effect at 90
th
 min (D% = +102.26 ± 49.01 and +173.10 ± 97.88, respectively). In contrast, 
analyses on the effects of lower dosages of CAP showed no statistical differences compared 
with baseline. Lastly, a between-treatments ANOVA was performed to compare the effects of 
different doses of CAP. No changes were observed for the time of onset comparing CAP at 10 
mg/kg with CAP at 5 and 1 mg/kg and controls. Instead, the duration of MDA and AD in 
CAP 10-treated animals was significantly increased with respect to CAP at 5, 1 mg/kg and 
controls (for P<0.05; fig. 17 a and as represented in fig. 7 d). 
Effect of single doses of capsazepine on % of responses and MDA parameters 
Three drug doses (0.5, 1 or 2 mg/kg, i.p.) were administered in order to evaluate the effects of 
capsazepine in different groups. All animals treated with CPZ responded to AB stimulation 
(% of protection = 0). Then, a within-subject analysis was performed for MDA parameters. 
CPZ at 2 mg/kg was able to significantly increase the duration of time of onset (F(18,95) = 2.35, 
P = 0.0041) as well to reduce MDA (F(18,95) = 3.47, P<0.0001) and AD (F(18,95) = 3.47, 
P<0.0001; fig. 17 b) durations. Post-hoc test showed that these effects were distributed from 
20
th
 to 160
th
 min with a maximum effect at 100
th
 min (D% onset = +31.54 ± 11.36; D% MDA 
duration = −42.95 ± 2.77; D% AD duration = −64.81 ± 7.94). The administration of CPZ at 1 
and 0.5 mg/kg did not induce any changes in MDA parameters when compared to baseline 
values. As for between-treatments comparisons, CPZ at 2 mg/kg significantly increased onset 
duration when compared to CPZ at 0.5 mg/kg and controls, but not versus CPZ at 1 mg/kg. 
Furthermore, the duration of MDA and AD in CPZ 2 mg/kg was statistically reduced with 
respect to CPZ at 0.5 and 1 mg/kg and controls (for P<0.05; fig. 17 b). 
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Fig. 17. (a) Effects of CAP at 10, 5 and 1 mg/kg on the time course of MDA parameters during the 18 
progressive stimuli. Each value represents the mean of D% ± S.D. of each treatment per stimulus 
versus baseline values (● CAP 10 mg/kg, ● CAP 5 mg/kg, ● CAP 1 mg/kg). Within-treatment 
statistically significant D% of CAP at 10 mg/kg is indicated as (*) for P<0.05 vs baseline values. 
Between-treatments significance of CAP at 10 mg/kg was indicated as (◦) for P<0.05 versus CAP 5 
and 1 mg/kg. (b) Effects of CPZ at 2, 1 and 0.5 mg/kg on MDA parameters during 18 stimuli. Each 
value represents the mean of D% ± S.D. of each treatment per stimulus versus baseline values (● CPZ 
2 mg/kg, ● CPZ 1 mg/kg, ● CPZ 0.5 mg/kg). Within-treatment statistically significant D% of CPZ at 
2 mg/kg is indicated as (*) for P<0.05 versus baseline values. Between-treatments significance of CPZ 
2 mg/kg was indicated as (◦) for P<0.05 versus CPZ 1 and 0.5 mg/kg, and as (+) for P<0.05 only 
versus CPZ 0.5 mg/kg. 
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Effect of capsaicin on % of responses and MDA parameters of rats treated with 
WIN at 10 mg/kg 
 
Fig. 18. (a) Effects of co-treatment with CAP at 10 mg/kg and WIN at 10 mg/kg on % MDA 
protection versus WIN at 10 mg/kg. (b) Effects of co-treatment on MDA parameters during 18 stimuli 
compared with WIN at 10 mg/kg. Each value represents the mean of D% ± S.D. of each treatment per 
stimulus versus baseline values ( ■ CAP-WIN, ● WIN 10 mg/kg). Within-treatment statistically 
significant D% is indicated for P < 0.05 (* for both groups, § for co-treatment, # for WIN group) 
versus baseline values. 
When animals were co-treated with both CAP at 10 mg/kg and the WIN dose of 10 mg/kg, 
the % of protection was reduced when compared to WIN 10 mg/kg (Fig. 18 a) and the 
duration of this protection was limited from 20
th
 to 40
th
 min, but significant only at 20
th
 min 
when 33.33% of animals responded to AB stimulation (χ2 = 6.00, DF = 1, P=0.0014) (Tab. 5).  
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Furthermore, a within-treatment analysis showed that the co-treatment with CAP and WIN 
induced significant changes on MDA parameters with respect to baseline. The time of onset 
was not statistically different, but significant reductions were found for MDA (F(18,89) = 2.89, 
P=0.0005) and AD (F(18,89) = 4.0, P=0.0001). Post-hoc tests showed that MDA was decreased 
from 30
th
 to 120
th
 min, with a maximum effect at 30
th
 min (D% = −47.57 ± 6.31); while AD 
was reduced from 20
th
 to 120
th
 min with a maximum effect at 30
th
 min (D% = −63.67 ± 
25.30). Between-treatments comparisons were performed between the co-treated group versus 
WIN 10 and controls (Fig. 18 b). Though, for all parameters it is evident a weaker effect of 
the co-administration of CAP and WIN with respect to WIN alone, the between-treatments 
analysis did not reach statistical significance. However, the co-treated group maintains a 
significant antiepileptic effect when compared to controls. 
Effect of capsazepine on % of responses and MDA parameters of rats treated 
with WIN at 10 mg/kg 
The co-administration of CPZ at 2 mg/kg and WIN at 10 mg/kg noticeably enhanced the % of 
protection with respect to WIN 10 mg/kg (Tab. 5 and fig. 19 a). Indeed, a clear protection was 
found from 20
th
 to 140
th
 min, with significant values up to 110
th
 min and a maximal effect at 
20
th
 to 50
th
 interval when only 33.3% of animals responded to AB stimulation (χ2= 6.00, DF = 
1, P=0.0014). Moreover, a within-treatment analysis on MDA parameters revealed that there 
was both a significant increase in the onset time (F(18,56) = 6.01, P<0.0001) and a reduction in 
MDA (F(18,56) = 11.69, P<0.0001) and AD (F(18,56) = 7.06, P<0.0001), when compared to 
baseline. Post-hoc tests showed that onset was increased from 10
th
 to 110
th
 min, with a 
maximal effect at 30
th
 min (D% = +68.33 ± 30.64); MDA and AD went down from 10
th
 to 
140
th
 min with a maximum effect at 60
th
  min (D%(D% = −77.36 ± 10.87) and at 20th min 
(D% = −99.09 ± 1.29), respectively. Between-treatments comparisons were performed on co-
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treated group with respect to WIN 10 mg/kg and controls (Fig. 19 b). Analyses on differences 
versus WIN 10 mg/kg showed no statistical changes on MDA parameters. Lastly, the co-
treated group shows a marked antiepileptic effect when compared to controls. 
 
 
Fig. 19. (a) Effects of co-treatment with CPZ at 2 mg/kg and WIN at 10 mg/kg on % MDA protection 
versus WIN at 10 mg/kg. (b) Effects of co-treatment on MDA parameters during 18 stimuli compared 
with WIN at 10 mg/kg. Each value represents the mean of D% ± S.D. of each treatment per stimulus 
versus baseline values (▼ CPZ 2 mg/kg and WIN 10 mg/kg, ● WIN 10 mg/kg). Within-treatment 
statistically significant D% is indicated for P<0.05 (* for both groups, § for co-treatment, # for WIN 
group) versus baseline values. 
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Effect of capsazepine on % of responses and MDA parameters of rats treated 
with WIN at 5 mg/kg 
CPZ was also administered with the subeffective dose of WIN. Pre-treatment with CPZ at 2 
mg/kg of animals treated with WIN at 5 mg/kg, did not modify the % of protection with 
respect to WIN 5 mg/kg, but significantly influenced MDA parameters (Table 5 and fig. 20 
a). Indeed, the duration of the onset was significantly increased (F(18,89) = 2.54, P=0.0021), 
and reductions were found for MDA (F(18,89) = 5.9, P<0.0001) and AD (F(18,89) = 5.9, 
P<0.0001). Post-hoc tests highlighted that onset was changed from 40
th
 to 60
th
 and from 90
th
 
to 130
th
 min with a maximum effect at 40
th
 min (D% = +40.21 ± 29.83); while MDA and AD 
from 10
th
 to 170
th
 min with a maximum effect at 40
th
  min (D% = −47.84 ± 7.61) and at 60th 
min (D% = −74.06 ± 10.69), respectively.  
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Fig. 20. (a) Effects of co-treatment with CPZ at 2 mg/kg and WIN at 5 mg/kg on % MDA protection 
versus WIN at 5 mg/kg. (b) Effects of co-treatment on MDA parameters during 18 stimuli compared 
with WIN at 5 mg/kg. Each value represents the mean of D% ± S.D. of each treatment per stimulus 
versus baseline values (■ CPZ 2 mg/kg and WIN 5 mg/kg,  ● WIN 5 mg/kg). Within-treatment 
statistically significant D% is indicated for P<0.05 (§ for co-treatment) versus baseline values. 
Between-treatments significance of co-treated group was indicated as (◦) for P<0.05 versus WIN 5 
mg/kg. 
Between-treatments analyses were conducted on CPZ co-administered with WIN at 5 mg/kg 
versus WIN 5 mg/kg, CPZ at 2 mg/kg and controls. Significant changes were found for MDA 
and AD durations versus the ineffective WIN dose of 5 mg/kg (for P < 0.05). Lastly, CPZ–
WIN showed significant reductions of MDA and AD duration at 30
th
 and 120
th
 min versus 
CPZ at 2 mg/kg (for P<0.05; fig. 20 b). 
Effect of capsaicin on % of responses and MDA parameters of rats treated  with 
WIN at 10 mg/kg after 7NI or ARG administration 
 
Fig. 21. Effects of 7NI-CAP-WIN and ARG-CAP-WIN groups on the time course of MDA 
parameters during the 15 progressive stimuli. Each value represents the mean of D% of each treatment 
(♦7NI-CAP-WIN or ♦ ARG-CAP-WIN) per stimulus versus baseline values. Within-treatment 
statistically significant D% of 7NI-CAP-WIN is indicated for P<0.05 (*) vs baseline values. Between-
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treatments significance of 7NI-CAP-WIN group was indicated as (◦) for P<0.05 versus ARG-CAP-
WIN. 
The co-treatment of 7NI and CAP on WIN reduced % MDA response from 10
th
 to 80
th
 min 
versus vehicle-treated controls, reaching significance at the 20
th
 and 30
th
 (MDA responses = 
33%; χ2= 6.000, DF= 1, P=0.0143; tab. 5). As for MDA parameters, within-treatment analysis 
showed a significant increase in time of onset (F(15,63) = 1.877, P=0.043) and a decrease in 
MDA and AD durations (F(15,63) = 2.21,  P=0.0146 and F(15,63) = 1.856; P= 0.045, respectively; 
fig.21). Post-hoc comparisons outlined that the increase in the onset was maximal at 40
th
 min 
(D%= 75.59 ± 32.23); while the reductions in MDA and AD were framed between the 10
th
 
and the 110
th
  with a maximum effect at the 30
th
 (D%= -69.67 ± 5.05 and D%= -80.76 ± 11. 
77, respectively; fig.21).   
The administration of ARG before CAP and WIN reduced the number of responding animals 
from 10
th
 to 40
th
 min versus vehicle-treated controls, but a significant change was induced 
only at the 20
th
 (MDA responses = 50%; χ2= 4.000, DF= 1, P=0.0045; tab. 5). Though the 
time course of onset seemed to have increased while MDA and AD durations were reduced, 
analysis on MDA parameters did not show any significant difference versus related baseline 
values (Fig.21). Between-treatments significant differences were found comparing 7NI-CAP-
WIN with ARG-CAP-WIN groups. The time of onset in 7NI-CAP-WIN group was increased 
from 20
th
 to 40
th
 min and MDA and AD durations were lowered ranging from the 10
th
 to 40
th
 
(P<0.05, fig.21). 
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DISCUSSION 
Epileptic seizures originate from mechanisms altering the balance between excitation and 
inhibition of neuronal transmission. Electrical bases governing synaptic processes are thus 
fundamental aspects to consider. Animal research is crucial for investigating on synaptic 
mechanisms involved in seizures, giving opportunities to advance our understanding of 
epileptogenesis and hence the potential to treat. The most common epilepsy models elicit 
seizures in adult male rodents, via injection of a proconvulsant drug (i.e. pilocarpine and 
kainic acid) or electrical stimulation (Löscher, 2011). Administration of anticonvulsants after 
the onset can limit the occurring widespread damage to the brain, similarly as observed in 
humans (Scharfman et al., 2007). A direct consequence is that employing a double in vivo 
experimental approach could pose solid ground for determination of possible causes and 
individuate specific therapeutic improvements. In this view, in the present study the data were 
obtained by employing two models of TLE that are considered as a powerful tool to predict 
the response to new antiepileptic treatments (Banach et al., 2011; Curia et al., 2008). These 
models determine acute seizure events in naïve animals, due to different epileptogenic 
mechanisms respectively based on electrical stimulation and chemical triggering, in order to 
explore fundamental aspects of paroxysmal discharge underlying symptomatic epileptic state.  
Insight into cannabinoid contribution to epileptic seizures 
This research provides an insight into the contribution of cannabinoid-mediated synaptic 
mechanisms in rat models of epileptic seizures. Preclinical testing of cannabinoids in the last 
decades have boosted interest on their pharmacological power in epilepsy (Ligresti et al., 
2016; Pertwee, 2012; Howlett et al., 2004; Wallace et al., 2001), despite therapeutic 
application may expose to acute and chronic side effects (Hill et al., 2012; Gerra et al., 2010). 
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However, the exact molecular mechanisms of exogenous and endogenous cannabinoids in the 
complex regulation of normal and paroxysmal neuronal excitability remains elusive.  
In my experiments, synthetic CB agonist WIN was tested, as an ideal candidate to explore the 
outcomes of pharmacological activation of endocannabinoid system, since it has been used in 
numerous models of epileptic seizures and also its antiepileptic effect was found to go beyond 
CB1-dependence in models of temporal lobe epilepsy (Suleymanova et al., 2016; 
Payandehmer et al., 2015; Hill et al., 2013; Rizzo et al., 2009; Jones et al., 2012, Wallace et 
al., 2003). The present results showed that WIN administration at increasing dosages exerts a 
dose-dependent protection. In that, WIN at 10 mg/kg markedly dampened paroxysmal 
responses along the entire observation period, while WIN at 5 mg/kg action was scarcely 
effective and of short duration (within 40 minutes post-treatment) and WIN at 1 mg/kg did 
not prevent MDA responses at all. Similarly, focusing on MDA parameters, WIN at the 
effective dose of 10 mg/kg showed a marked action in decreasing ictal events severity from 
20
th
 min of observation on, with respect to WIN at lower doses that do not significantly 
modify electric activity. As a matter of fact, CB1 receptors located in the pre-synaptic 
terminals of central synapses stabilize membrane potentials by adjusting ion currents and 
inhibit the release of neurotransmitters (Pan et al., 1996; Deadwyler et al., 1995). 
Accordingly, cannabinoids participate to short- and long- term synaptic plasticity including: 
depolarization-induced suppression of excitation (DSE) and inhibition (DSI) by respectively 
reducing glutamate or GABA, or long-term depression of excitatory and inhibitory signals 
(Ligresti et al., 20161; Kreitzer and Regehr, 2001; Ohno-Shosaku  et al., 2001; Wilson and 
Nicoll, 2001). In detail, CB1-mediated DSE has been hypothesized to be involved in the 
reduction of the seizure discharge in hippocampal cultures (Deshpande et al., 2007). A 
prominent line of research tend to support that the antiepileptic properties of CB agonists may 
be due to a modulation mainly directed towards the inhibition of the glutamatergic 
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neurotransmission rather than GABA release (Monory et al., 2006). Indeed, the importance of 
cannabinoid modulation of excitatory glutamatergic transmission is strongly suggested by the 
widely reported presence of CB1R in glutamatergic terminals whose altered expression is 
associated to an unbalance of neuronal excitability driving to pro-epileptic states (Ludànyi et 
al., 2008; Monory et al., 2006; Lutz, 2004). Though, in the MDA experimental rat model of 
focal epilepsy, the lack of a complete blockade of WIN-induced effect after pre-treatment 
with a selective CB1 antagonist, AM251, (Rizzo et al., 2009) raised the possibility of further 
mechanisms for CB-mediated modulation of hippocampal seizures. In this regard, several 
evidence report a wide distribution of CB2R in neuronal and glial cells in different CNS areas 
such as cerebral cortex, hippocampus, thalamus, brain stem and cerebellum (Gong et al., 
2006), suggesting a potential implication of CB2 receptors, besides CB1R role, in mediating 
CB signalling (García-Gutiérrez et al., 2012). To complete the pharmacological 
characterization of WIN on CB receptors, it was administered the antagonist/inverse agonist, 
AM630, known for its high potency and affinity for rat CB2 receptors (Bolognini et al., 2012; 
Mukherjee et al., 2004). These results showed that, when compared to the effect induced by 
WIN alone, the co-treatment with AM630 and WIN significantly reduced the severity of ictal 
events and, even more, the percentage of responses to the stimulation, suggesting that AM630 
improves WIN efficacy. A possible reduced proneness to the epileptogenic phenomena, as 
revealed by the increase of onset time, is not associated to significant differences in MDA and 
AD parameters between the AM630-WIN and WIN groups. Taken together, these data might 
suggest that the efficacy of the co-treatment is exerted mainly by augmenting seizure 
threshold in the DG, rather than on the epileptic discharge, once elicited. On the basis of the 
enhancement of WIN-induced effects following AM630 pretreatment, one group of animals 
was treated with the CB2 antagonist/inverse agonist to assess its efficacy when administered 
alone, but this treatment did not alter the characteristics of epileptic discharge, suggesting that 
 61 
 
CB2 exerts no direct effects on hippocampal hyperexcitability in MDA model. From a 
pharmacodynamic point of view, it can be hypothesized that WIN may have greater 
occupancy at CB1R when CB2 receptors are antagonized by AM630, hence eliciting a better 
response by facilitating WIN selectivity on CB1-mediated pathway. Considering that the 
present study suggest the endogenous CB1R, rather than CB2, to be majorly implicated in 
WIN modulation of hyperexcitability, it is of interest to unveil the downstream pathway 
involved in cannabinoid complex antiepileptic mechanisms, apart from the well-known CB1-
dependent retrograde signalling (Payandemehr et al., 2015; Hill et al., 2013; Jones et al., 
2012).  In this regard, the eCB system and NO/cGMP signalling were found to be mutually 
involved in several processes in the CNS (Azad et al., 2001; Ghasemi et al., 2007; Howlett et 
al., 2004; Stefano et al., 1998). 
Putative implication of NO/cGMP signalling in CB effects in the MDA model 
In line with this, the subsequent objective that I pointed to follow was the influence of 
nitrergic system in cannabinoid effects within the context of hyperexcitability. Authors have 
reported that in the brain excitability and synaptic function may be oppositely modulated by 
either endogenous CB signalling or NO-dependent cGMP pathway, for instance through the 
control on neurotransmitter release and ion channels conductance (Castillo et al., 2012; Ahern 
et al., 2002; Robello et al., 1996). To this point, our laboratory previously yielded evidence of 
the importance of nNOS/sGC on MDA phenomena (Sardo et al., 2006) and on the modulation 
of therapeutic potential of anti-epileptic drugs (Ferraro and Sardo, 2009; Sardo et al., 2009; 
2008). The usage of different drugs active on nitrergic pathway is aimed to individuate 
eventual points of interaction with cannabinoid system. Initially, it was tested 7NI, a 
preferential nNOS inhibitor, blocking NO synthesis, that was reported to modulate epileptic 
phenomena with a neuroprotective effect (Banach et al., 2011; Sardo et al., 2006; Borowicz et 
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al., 2000). In a dose-response assessment in the MDA model, 7NI distinctly reduced the 
number of MDA responses to the AB stimulation only when administered at 50 mg/kg; 
whereas 7NI at 35 and 20 mg/kg showed weaker effects. As well, 7NI significantly reduced 
the durations of MDA and AD parameters only after treatment at 50 mg/kg, also when 
compared with lower doses. This is in line with what previously found about treatments 
reducing NO levels in the brain, but also drugs as ODQ, impairing NO-dependent cGMP-
activated pathway, via the blockade of sGC (Banach et al., 2011; Sardo et al., 2006). 
After this step, aiming to test if a combination of drugs could improve single treatment 
efficacy, doses that individually resulted non-effective were co-administered, so that the 
possible appearance of an effect would be attributable to their simultaneous action. To this 
purpose, in the MDA model animals were pre-treated with 7NI at 20 mg/kg before WIN at 5 
mg/kg. My data recorded a noticeable boost of protection in 7NI pre-treated animals, 
highlighting a potentiation of antiepileptic outcomes within the presumed time frame of WIN 
efficacy. As a matter of fact, the scarce effect on the percentage of protection displayed by 
single injection of WIN at 5 mg/kg became significant, in the same lapse of time, when 7NI 
comes into play. Similarly, MDA parameters were significantly altered in 7NI-WIN group 
with a dampened susceptibility to epileptic discharge and a reduced intensity of paroxysmal 
activity once elicited, within the timeframe of WIN efficacy starting from the first 10
th
 min. 
All together, these data may hint that the interplay managed to control the typical 
manifestations of the MDA. However, it is conceivable that the co-treatment reduced the 
excitability of DG neurons, preventing their proneness to altered discharge, via a probable 
augmentation of the activation threshold in the context of the glutamatergic hippocampal–
parahippocampal circuitry. Effects of 7NI–WIN co-administration were counteracted pre-
treating animals with AM251; indeed, in this group the protection against MDA disappeared 
and MDA parameters were not significantly modified compared to controls. Hence, this 
 63 
 
outlines the influence of CB1 receptors in the control of MDA-induced epileptogenesis and 
that a linkage in the communication between CB and NO systems is represented by CB1R-
activated mechanisms. In this context, to further explore the contribution of NO production in 
CB effects, I administered arginine, the precursor of the synthesis of NO from nNOS, that 
previous reports individuated as a pro-convulsant that increases levels of nNOS in epileptic 
models (Sardo et al., 2006; Bhardwaj et al., 1997). When ARG is co-administered with WIN 
at maximal dose, protective effects of WIN are reduced, especially regarding severity of 
paroxysmal discharge. Indeed, MDA parameters did not appear to be modified versus 
baseline, though a non-significant reduction of MDA responses is found in the early 
stimulations. These opposed outcomes confirmed the specific implication of nitric oxide 
production in WIN-mediated effects.  
Since NO primary target is cGMP-activated signalling cascades, it would be a point of 
interest to assess if NO downstream effector is implicated in cannabinoid neuromodulation. 
Indeed, the administration of ODQ alone, a specific inhibitor of the sGC, was previously 
discovered by Sardo et al., 2006 to induce a significant decrease of the severity of ictal events, 
but no change in the MDA responses, in any case suggesting a functional involvement of the 
NO/sGC metabolic pathway in the DG paroxysmal activity. In this light, in the present 
research, animals were co-treated with WIN and ODQ. The percentage of responses 
impressively fell when compared to WIN alone, thus suggesting the presence of a stronger 
control of the excitability of DG neurons by concomitant sGC inhibition and CB activation. 
The current electrophysiological data providing evidence to the hypothesis of NO-CB co-role, 
support other findings strongly bridging NO and eCB inasmuch as regulating neuronal 
hyperexcitability in pathophysiological states (Bahremand et al., 2009; Jones et al., 2008; 
Makara et al., 2007; Stringer and Erden, 1995). Nevertheless, studies about the 
pathophysiology of epileptic phenomena may produce conflicting results, (Lӧscher, 2011; 
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Lӧscher et al., 1991), therefore the promising treatment with the subeffective doses of NO-
active and CB drugs were tested in pilocarpine acute model of TLE in order to provide a 
further behavioural characterization.  
Involvement of NO/cGMP signalling in CB effects in the pilocarpine model 
In the pilocarpine model, WIN and 7NI were initially administered alone to assess their 
impact on the behavioural manifestations of acute epileptic phenomena. The onset of 
pilocarpine maximal effect, as reported in the literature (Curia et al., 2008), is recorded 
around half an hour after pilocarpine injection, reaching the most severe scores, but symptoms 
lasts for hours. When individually administered, the effective doses of WIN (10 and 5 mg/kg) 
and 7NI (50 and 35 mg/kg) not only averted score-5 seizures within the two-hour 
observations, but also reduced related mortality, according to a dose-dependent pattern. The 
high mortality rate here observed in control rats is consistent with the data on mortality of rats 
after 24 hours pilocarpine SE reported by other groups (Jones et al., 2012; Cuellar-Herrera et 
al., 2010). 
My study has shown that a single administration of WIN at maximal dose dramatically boosts 
survival up to 100%. This favourable effect of WIN on post-SE mortality could be also due to 
its anti-inflammatory, hypothermic and anti-oxidative effects (Suleymanova et al., 2016; Ma 
et al., 2014; Marchalant et al., 2007).  Moreover, animals treated with WIN or 7NI at the 
effective doses displayed the less severe signs of pilocarpine scoring scale along the 
observation period. Particularly, the effect of WIN at 10 mg/kg started immediately, 
attenuated the intensity of pilocarpine-induced seizures from 30 min and averted behavioural 
symptoms from 90 to 120 min of the experimental session; whereas, the administration of 7NI 
at both 50 and 35 mg/kg was effective in thwarting the intensity of seizure scores within the 
observation, though only in the last 70 minutes, without influencing latency. In support of a 
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more complete action of WIN, latencies to the first seizure state were also affected in WIN at 
10 mg/kg. WIN at 5 mg/kg had a similar ongoing, though it did not properly protect animals 
within the pilocarpine maximal effect. WIN activity was displayed to be dependent on CB1 
receptors activation in that the CB1 antagonist, AM251, counteracts WIN effective dose and 
this represents a first specific outcome about CB1R role in the acute pilocarpine model. In 
analogy with the MDA experimental procedures, having found WIN at 1 mg/kg and 7NI 20 
mg/kg as ineffective doses for the parameters considered in this model, a parallel co-treatment 
study was conducted to explore behavioural outcomes, as well. The injection of WIN and 7NI 
protected animals from severe seizures and mortality within 24 h, similarly to the individual 
effective doses of WIN and 7NI. Noticeably too, the co-treatment emerged as fruitful in 
delaying the latency of pilocarpine-induced onset and attenuating the intensity of behavioural 
symptoms within the experimental period, without the side effects observed here for the 
higher doses of cannabinoids and reported previously (Wallace et al., 2003; 2001). Otherwise, 
pretreatment with AM251 reverts 7NI–WIN protection from the most severe seizures and, 
consistently, reduced latency to first symptoms and increased mortality versus 7NI-WIN 
alone, thereby highlighting the importance of CB1R not only in the activity of WIN alone but 
also in the 7NI potentiation of WIN effects.  
Since behavioural results supply a novel behavioural characterization of the drugs used, it is 
worth speculating on the probable synaptic processes involved. In the acute pilocarpine 
model, the chemo-convulsant acts on the muscarinic acetylcholine receptor (mAChr) M1 
subtype, responsible for seizure initiation, and consequently triggers NMDA signalling, 
implicated in seizure maintenance (Curia et al., 2008 ; Hamilton et al., 1997; Clifford et al., 
1987). Interestingly enough, WIN, but not 7NI, was able to delay the onset of first seizure 
signs, hinting the idea that only CB agonism could counterbalance muscarinic 
epileptogenesis. A neuroprotective production of endocannabinoids following mAChr 
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activation in mouse pilocarpine model was indeed found (Kow et al., 2014); thus, 
conceivably, NO signalling is not involved in seizure initiation. Furthermore, treatments with 
WIN or 7NI attenuate the intensity of behavioural signs, due to the possible mitigation of 
NMDA-mediated seizure maintenance (Kow et al., 2014). In this regard, these data support 
the idea that both cannabinoid and nitrergic systems act on NMDA excitatory pathways, 
maybe through independent mechanisms (Howlett et al., 2010; Fagni and Bockaert, 1996), 
and this common synaptic target may be responsible for their individual and synergic 
antiepileptic activity. Notably, the co-treatment may influence both mAChr-induced initiation 
and NMDA-sustained maintenance of seizures in this model, in line with the action of WIN 
alone when effective, hence leaning toward a possible facilitation of CB-mediated pathway 
following nNOS blockade. Moreover, it is arguable that a possible involvement of NO is to be 
considered downstream CB activation, especially for muscarinic phase. This is in agreement 
with data here obtained from MDA model since, by modulating nNOS and sGC activity via 
diverse drugs, nitrergic pathway could be hypothesized to be targeted as a neuromodulator 
after previous CB1 activation (e.g. under WIN application).  
It can be asserted that nNOS inhibition in particular promotes a potentiation of CB effects, 
since I observed that antiepileptic actions were boosted within an early time frame that in the 
initial dose-dependent studies in the two models was pointed out as mainly subjected to WIN 
action, consistently with other reports both on WIN and 7NI dynamics (Rizzo et al., 
2009;Valiveti et al., 2007; Kalisch et al., 1996). At molecular level, a recent perspective 
implies CB receptors and NO also via the co-internalization of CB1R and NR1 subunit of 
NMDA in order to offset against NO production, with the ultimate goal of overriding CB 
protection from brain damage (Sánchez-Blázquez et al., 2013). My results, obtained through 
CB1R inhibition before 7NI–WIN co-treatment, well fit within this context and show that 
cooperation between the effects of 7NI and WIN stops when CB1 activation is cut out. On this 
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point, though my experimental approach does not allow us to discriminate whether the 
cooperative action of WIN and 7NI is due to linked or independent networks, several 
evidence point to a control of CB1R pathway on the production of NO by NOS isoforms. 
Indeed, in mice neuron cultures it was observed that the inhibition of NO production by WIN 
is reversed in CB1R-knockouts, along with an increased basal activity of nNOS (Kim et al., 
2006 b). It was suggested that CB1R exerts the abovementioned effect on NO production 
decreasing the calcium influx and therefore the activity of Ca-dependent nNOS isoform 
(Hillard et al., 1999). In this view, cannabinoid ability to reduce the release of glutamate from 
synaptic terminals could impair NMDA-dependent calcium signalling, thus lowering post-
synaptic Ca-mediated NO production and ultimately impairing cGMP formation (Fig. 22). 
 
 
Fig. 22. Representation of the molecular players targeted by WIN, 7NI and ODQ. Considering 
pre-synaptic CB1 localization in glutamatergic (GLU) terminals, WIN could reduce GLU release, 
lowering post-synaptic intracellular Ca
2+
 that is essential for NO production and consequent activation 
of pre-synaptic sGC. 
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Taken together, the co-treatment results, applying 7NI, ODQ and ARG to cannabinoid-
activated cells, added knowledge to the formerly suggested interplay between cannabinoid 
and nitrergic systems in the context of synaptic transmission (Hillard et al., 1999), particularly 
regarding the mechanisms underlying neuronal excitotoxicity (Kim et al., 2006 a). Indeed, my 
study seem to confirm a functional antagonism between CB receptors and NO, since the 
hindrance of NO signalling favours CB-mediated antiepileptic actions, though on this issue 
there are still no concerted opinions in literature. In accordance with these findings, growing 
pieces of evidence prompted to suggest that blocking nNOS via 7NI treatment protects 
against hyperexcitability phenomena (Banach et al., 2011; Takei et al., 2001) and other 
neurodegenerative processes (Yuste et al., 2012; Bostanci and Bagirici 2007; Hantraye et al., 
1996). Noteworthy, albeit main analogies, some variances came to light as concerns the 
protective doses in the two models, putatively due to the different mechanisms behind 
epileptic phenomena, and this led to the choice of distinct WIN doses for the co-treatments. 
On the other hand, opposite results on the influence of 7NI on CB agonists were reported in 
another model of epilepsy in mice (Bahremand et al., 2009), in agreement with other authors 
claiming the pro-convulsant activity of NOS inhibitors (de Vasconcelos et al., 2000; Del-Bel 
et al., 1997; Przegalinski et al., 1996). The difficulty of fully understanding the function of 
nitrergic system in epileptic studies is prominent (Banach et al., 2011), since discrepancies 
arise even using the same protocol (Payandemehr et al., 2014; Bahremand et al., 2009; Van 
Leeuwen et al., 1995), but especially with differential paradigms, species and treatments 
(Löscher et al., 1991). This validates the effort to use a dual experimental approach to provide 
a wider perspective of the CB–NO cross-talk in the epileptogenic phenomena. Lastly, the 
CB–NO possible interaction here assessed in the context of the modulation of paroxysmal 
events, may have a broader connotation. Indeed, these systems mutually exert a refined 
control of synaptic transmission with a relapse on multiple processes in various brain areas 
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(Kim et al., 2006a, b; Hillard et al., 1999; Waksman et al., 1999), postulating nNOS activity 
as modulated by cannabinoid effects. 
All this evidence support the idea that the activation of CB1-pathway could have among its 
downstream effects the blockade of post-synaptic NO production, directly targeting nNOS or 
more complex cellular mechanisms. 
Further factors involved in CB signalling in electrically-induced seizures 
Among CB-mediated complex cellular mechanisms, the subsequent aim of this study 
endorsed recent trends on the relevance of cannabinoid post-synaptic signalling, directed 
specifically towards CB1 receptors or CB1-activated downstream processes. Indeed, TRPV1 
has emerged as a mediator of CB post-synaptic cascades since vanilloids were found to be 
implicated in the fine tuning of CB-induced regulation of synaptic strength in various 
processes (Di Marzo and De Petrocellis, 2012), particularly in different experimental models 
of epilepsy (Jia et al., 2015; Naderi et al., 2015; Gonzalez-Reyes et al., 2013; Manna and 
Umathe, 2012; Fu et al., 2009). To serve the purpose of assessing the possible role of TRPV1 
in cannabinoid-induced antiepileptic effect, I pharmacologically manipulated with TRPV1-
active drugs the pathway triggered by WIN, that has been reported to exhibit a variegated 
activity on TRP channels (De Petrocellis and Di Marzo, 2010; Qin et al., 2008).  
At first, the single involvement of TRPV1 in the modulation of MDA-related 
electrophysiological phenomena was analysed. Animals were treated with different doses of 
the couple of TRPV1 agonist and antagonist mostly used in this field: capsaicin and 
capsazepine. The highest dose of CAP produced an intensification of the epileptic discharge 
characterized by related changes in the MDA parameters, i.e., reduction of time of onset and 
elongation of MDA and AD durations. What was here found is in line with other reports 
describing CAP promoting firing rate in epileptic hippocampal slices (Saffarzadeh et al., 
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2015; Kawahara et al., 2011; Bhaskaran and Smith, 2010) and showing pro-convulsant 
activity in behavioural models (Jia et al., 2015). A similar dose-response evaluation was 
conducted for CPZ-treated groups. The only dose that resulted effective was the highest one 
(2 mg/kg). In this case, the effects were opposite to CAP: increase of the time of onset and 
shortening of MDA and AD durations, therefore showing an antiepileptic outcome and 
suggesting that in a hyperexcited state TRPV1 channels could be tonically active. Never did 
CPZ arrest MDA response after AB stimulation. In the light of this initial evidence, a 
modulation by TRPV1 of paroxysmal MDA events, quantitatively and qualitatively distinct 
from WIN antiepileptic effects, emerged.  
Taken this into account, WIN effects were subsequently evaluated co-administering animals 
with CAP or CPZ. In CAP–WIN group, the % of protection from MDA was reduced with 
respect to single WIN action at 10 mg/kg, also limiting the interval in which WIN is able to 
block MDA response. Conversely, to antagonize TRPV1 function in the timeframe of CB1 
antiepileptic action, CPZ at 2 mg/kg was administered before the effective dose of WIN. It 
resulted that WIN and CPZ action was potentiated with respect to WIN at 10 mg/kg, 
especially in the % protection from MDA response, since the number of animals not 
responding to stimulation is markedly augmented. The lack of a correlated statistical power of 
changes in MDA parameters is probably due to the dampened number of animals responding 
to stimulation. Changes in the % of responding animals would indicate an involvement of 
TRPV1 on CB1R control of the susceptibility of DG neurons when electrically triggered, i.e., 
whether epileptic discharge starts or not. Considering CPZ–WIN ability to enhance 
antiepileptic outcomes, the influence of CPZ on the sub-effective dose of WIN at 5 mg/kg 
was then assessed. Results showed that % of protection from MDA was not altered after pre-
treatment with CPZ at 2 mg/kg, albeit the duration of MDA and AD parameters was 
statistically reduced when compared to group treated with only WIN at 5 mg/kg; hence this 
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combination likely managed to turn into effective to some extent the subeffective dose of 
WIN. Noteworthy, neither WIN 5 mg/kg alone was ever able to stop MDA response nor the 
co-treatment with CPZ influence the subeffective dose of WIN in the blockade of the 
paroxysmal discharge.  
This evidence shed light on the effects of capsaicin and capsazepine that in the recent years 
have been increasingly studied in different models of epilepsy, putatively modifying neuronal 
firing with opposite outcomes (Jia et al., 2015; Iannotti et al., 2014; Gonzalez-Reyes et al., 
2013; Manna and Umathe, 2012; Bhaskaran and Smith, 2010). It is established that the 
cation-channel TRPV1, when activated, induces neuronal depolarization and contributes to 
generate action potentials that ultimately facilitate the release of glutamate (Starowicz et al., 
2007; 2008; Xing and Li, 2007). Conversely, cannabinoid signalling has been recognized to 
act pre-synaptically by decreasing intracellular calcium overload and reducing 
neurotransmitters release (Freund et al., 2003; Alger, 2002), but also to trigger complex 
inhibitory pathways in the post-synaptic site, contributing to reduce excitability level such as 
the modulation of TRPV1 and nitrergic system (Castillo et al., 2012; Wang et al., 2012; Hong 
et al., 2009; fig. 23 a and b).  
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Fig. 23. a, b. Proposed mechanisms for CB-TRPV1 activity in the MDA. Neurotransmitter (NT) 
release is modulated by pre-synaptic CBR activation. The different excitability levels of DG neurons 
could be influenced by WIN administration acting on: post-synaptic CBR eliciting inhibitory 
pathways; TRPV1, responsible for cation currents or a possible impairment of CB system on TRPV1 
function. Continue arrows (  ) indicate the direct activation of receptors; the barred lines (  ) 
stand for antagonism or blockade of a process; dashed arrows (  ) show a modulatory action and 
spotted arrows of different thickness (  ) indicate TRPV1-cation currents of different intensity. 
Yang et al. hypothesized that WIN action is utter enough when exerted on CB1 and TRPV1 
co-localized at the post-synaptic terminal (2013). As a result, these receptors are subjected to 
a protein–protein interaction that can decline depolarizing currents, lastly suppressing 
TRPV1-linked downstream events. This reinforces the direct evidence that coincident CB1 
activation and TRPV1 antagonism facilitate antiepileptic outcomes, as well as TRPV1 
agonism interferes with CB1-mediated neuroprotection in hyperexcitability. A schematic 
representation of the possible sites of interplay of these systems is reported in fig. 23 c and d.  
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Fig. 23. c, d. Proposed mechanisms for CB-TRPV1 activity in the MDA. Capsaicin (CAP) and 
capsazepine (CPZ) oppositely gate post-synaptic TRPV1, hence modulating WIN effect on 
excitability levels. Continue arrows (  ) indicate the direct activation of receptors; the barred 
lines (  ) stand for antagonism or blockade of a process; dashed arrows (  ) show a 
modulatory action and spotted arrows of different thickness (  ) indicate TRPV1-cation currents 
of different intensity.  
Suggested points of interaction between cannabinoid and nitrergic systems in 
hyperexcitability 
A novel interpretation could be suggested considering the implication of post-synaptic NO in 
CB1-TRPV1 signalling that has been recently proposed in various neuronal processes (Batista 
et al., 2015; Aguiar et al., 2014; Zschenderlein et al., 2011). Indeed,  TRPV1 were found to 
target post-synaptic nNOS, since systemic administration of CAP increased NO synthesis in 
the hypothalamus and amygdala in rats, whereas TRPV1 antagonists revert the activity of NO 
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donors (Lisboa et al., 2013; Okere et al., 2000). Noteworthy, a relevant paper stated that long-
term potentiation in the lateral amygdala is dependent on TRPV1, gated by CAP and 
modulated by cannabinoids, with a relapse on NO-mediated glutamatergic transmission 
(Zschenderlein et al., 2011). These authors revealed that “anandamide modulates NO levels 
by two independent pathways: (1) diminishing the NOS activity via cannabinoids; and (2) 
stimulating NO synthesis via TRPV1”. Similarly, the activity of cannabinoids on behavioural 
responses was correlated to NO levels via modulation of TRPV1 (Batista et al., 2015). 
In this light, it could be hypothesized that in the hippocampal paroxysmal discharge TRPV1 
could affect the nitrergic modulation of the antiepileptic effects exerted by WIN. Thus, some 
pilot experiments were conducted co-administering 7NI or ARG before CAP and WIN in the 
MDA, in order to test if NO levels could alter capsaicin impairment of WIN effects. My 
results proved in both groups (7NI-CAP-WIN and ARG-CAP-WIN) the persistence of the 
antiepileptic effect of WIN, though its efficacy in presence of CAP was related to the nNOS 
activity. Indeed, considering MDA parameters, 7NI-CAP-WIN revealed a marked anti-
epileptic effect with respect to ARG-CAP-WIN and, as for the % of responses, 7NI was found 
to attenuate CAP impairment of WIN protective effects since animals did not respond to 
stimulation for a more extended period not only comparing with % of responses of ARG-
CAP-WIN group, but also with CAP-WIN treatment alone. Overall, I observed that the 
blockade or the promotion of the NO production modified oppositely the influence of CAP on 
WIN antiepileptic effects. These preliminary findings could corroborate the importance of NO 
in the intracellular action of TRPV1 and CB1 receptors. Noticeably, this modulatory 
mechanism may occur by an independent action of the two receptors converging on the same 
target or, alternatively, TRPV1 could represent a link between CB1 and nNOS functions. In 
particular, WIN effects on NO production may be exerted by the direct modulation of post-
synaptic TRPV1. 
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CONCLUSIVE REMARKS AND FUTURE PERSPECTIVES 
 
The present research yielded knowledge on novel CB1-dependent interactions in the 
modulation of neuronal function in the hippocampus within the remit of hyperexcitability 
phenomena.  
The current findings support the speculation that a pathophysiological unbalance of 
CB1/TRPV1 and nitrergic signalling systems could be associated with bioelectrical alterations 
of synaptic processes, thus influencing experimental epileptic conditions. Cannabinoids and 
related pharmacological tools stand out for their therapeutic implications in refractory, focal 
epilepsy that frequently fail to be controlled, though backward opinions claim that 
cannabinoid psychoactive toxicity make their use impractical. Remarkably, in this study, the 
pharmacological manipulation of CB pathway through nitrergic signalling was a promising 
strategy to finely tune WIN efficacy in two parallel models of temporal lobe epilepsy in the 
rat so as to abolish seizures, but to be devoid of adverse consequences. Nonetheless, further 
studies on epilepsy models are necessary to deepen understanding of mechanisms involved. 
The development of novel therapeutic agents enhancing anticonvulsant action of cannabinoids 
without unwanted side effects can establish a solid rationale for additional research to act on 
intractable seizures. Hence, pre-treatment with drugs acting on nitrergic system may have face 
validity within the clinical setting and this fosters the urgency to further explore the 
pharmacological potential properties of cannabinoids. 
_______________________________________________________ 
The results of this research have been included in the following recent publications:  
-“Carletti F, Gambino G, Rizzo V, Ferraro G, Sardo P. 2016. Epilepsy Research 122:56–65” 
-“Carletti F, Gambino G, Rizzo V, Ferraro G, Sardo P. 2015. Neuroscience 303:149–159”  
-“Rizzo V, Carletti F, Gambino G, Schiera G, Cannizzaro C, Ferraro G, Sardo P. 2014. 
Epilepsy Research 108 (10):1711–1718”.  
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